

John A Kanis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3894020/publications.pdf>

Version: 2024-02-01

732
papers

107,805
citations

246

143
h-index

220

308
g-index

766
all docs

766
docs citations

766
times ranked

61207
citing authors

#	ARTICLE	IF	CITATIONS
1	The application of FRAX in Ecuador. <i>Revista Colombiana De ReumatologÃa</i> , 2023, 30, 199-206.	0.1	2
2	Fracture risk assessment by the FRAX model. <i>Climacteric</i> , 2022, 25, 22-28.	2.4	20
3	Osteoporosis and fractures in women: the burden of disease. <i>Climacteric</i> , 2022, 25, 4-10.	2.4	71
4	Sex differences in recovery of quality of life 12 months post-fracture in community-dwelling older adults: analyses of the Australian arm of the International Costs and Utilities Related to Osteoporotic Fractures Study (AusICUROS). <i>Osteoporosis International</i> , 2022, 33, 67-75.	3.1	4
5	FRAX-based intervention thresholds for Pakistan. <i>Osteoporosis International</i> , 2022, 33, 105-112.	3.1	1
6	One leg standing time predicts fracture risk in older women independent of clinical risk factors and BMD. <i>Osteoporosis International</i> , 2022, 33, 185-194.	3.1	8
7	Prediction of imminent fracture risk in Canadian women and men aged 45Âyears or older: external validation of the Fracture Risk Evaluation Model (FREM). <i>Osteoporosis International</i> , 2022, 33, 57-66.	3.1	10
8	Costs of patient management over 18Âmonths following a hip, clinical vertebral, distal forearm, or proximal humerus fragility fracture in Franceâ€”results from the ICUROS study. <i>Osteoporosis International</i> , 2022, 33, 625-635.	3.1	5
9	Osteoporosis in Europe: a compendium of country-specific reports. <i>Archives of Osteoporosis</i> , 2022, 17, 23.	2.4	66
10	The global approach to rehabilitation following an osteoporotic fragility fracture: A review ofÂthe rehabilitation working group of the International Osteoporosis FoundationÂ(IOF) committee of scientific advisors. <i>Osteoporosis International</i> , 2022, 33, 527-540.	3.1	23
11	Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1311-1321.	4.7	16
12	FRAX. , 2022, , 89-99.		1
13	FREM predicts 10-year incident fracture risk independent of FRAXÂ® probability: a registry-based cohort study. <i>Osteoporosis International</i> , 2022, , 1.	3.1	1
14	Management of patients at very high risk of osteoporotic fractures through sequential treatments. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 695-714.	2.9	33
15	Assessment and management of imminent fracture risk in the setting of the fracture liaison service. <i>Osteoporosis International</i> , 2022, 33, 1185-1189.	3.1	6
16	Epidemiology of hip fracture in Qatar and development of a country specific FRAX model. <i>Archives of Osteoporosis</i> , 2022, 17, 49.	2.4	4
17	Prevalence of healthy aging among community dwelling adults age 70 and older from five European countries. <i>BMC Geriatrics</i> , 2022, 22, 174.	2.7	9
18	UK clinical guideline for the prevention and treatment of osteoporosis. <i>Archives of Osteoporosis</i> , 2022, 17, 58.	2.4	146

#	ARTICLE	IF	CITATIONS
19	Incidence of hip fracture in Saudi Arabia and the development of a FRAX model. Archives of Osteoporosis, 2022, 17, 56.	2.4	6
20	Improved fracture risk prediction by adding VFA-identified vertebral fracture data to BMD by DXA and clinical risk factors used in FRAX. Osteoporosis International, 2022, 33, 1725-1738.	3.1	13
21	Prevalence of polypharmacy in community-dwelling older adults from seven centres in five European countries: a cross-sectional study of DO-HEALTH. BMJ Open, 2022, 12, e051881.	1.9	11
22	Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nature Reviews Endocrinology, 2022, 18, 366-384.	9.6	42
23	Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporosis International, 2022, 33, 2103-2136.	3.1	33
24	Trabecular Bone Score Adjustment for the Fracture Risk Assessment Tool (FRAX [®]). Calcified Tissue International, 2022, 111, 226-227.	3.1	2
25	Bone Turnover Marker Profiling and Fracture Risk in Older Women: Fracture Risk from Age 75 to 90. Calcified Tissue International, 2022, 111, 288-299.	3.1	4
26	A micro-costing analysis of post-fracture care pathways: results from the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS). Osteoporosis International, 2022, 33, 1895-1907.	3.1	5
27	Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. Archives of Osteoporosis, 2022, 17, .	2.4	13
28	Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability—results from the Women's Health Initiative hormone therapy trials. Osteoporosis International, 2022, 33, 2297-2305.	3.1	9
29	An updated hip fracture incidence rate for Brazil: the Brazilian Validation Osteoporosis Study (BRAVOS). Archives of Osteoporosis, 2022, 17, .	2.4	1
30	Combining fracture outcomes in phase 3 trials of osteoporosis: an analysis of the effects of denosumab in postmenopausal women. Osteoporosis International, 2021, 32, 165-171.	3.1	6
31	Fracture risk assessment in celiac disease: a registry-based cohort study. Osteoporosis International, 2021, 32, 93-99.	3.1	11
32	Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures. Osteoporosis International, 2021, 32, 39-46.	3.1	26
33	The timed up and go test predicts fracture risk in older women independently of clinical risk factors and bone mineral density. Osteoporosis International, 2021, 32, 75-84.	3.1	28
34	Health service use pathways associated with recovery of quality of life at 12-months for individual fracture sites: Analyses of the International Costs and Utilities Related to Osteoporotic fractures Study (ICUROS). Bone, 2021, 144, 115805.	2.9	14
35	The use of 2-, 5-, and 10-year probabilities to characterize fracture risk after a recent sentinel fracture. Osteoporosis International, 2021, 32, 47-54.	3.1	21
36	Clodronate. Bone, 2021, 143, 115715.	2.9	13

#	ARTICLE	IF	CITATIONS
37	Fracture prediction from FRAX for Canadian ethnic groups: a registry-based cohort study. Osteoporosis International, 2021, 32, 113-122.	3.1	18
38	DO-HEALTH: Vitamin D3 - Omega-3 - Home exercise - Healthy aging and longevity trial - Design of a multinational clinical trial on healthy aging among European seniors. Contemporary Clinical Trials, 2021, 100, 106124.	1.8	28
39	A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis. Osteoporosis International, 2021, 32, 1301-1311.	3.1	9
40	Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. Osteoporosis International, 2021, 32, 585-594.	3.1	26
41	In memory of Harry K Genant. Osteoporosis International, 2021, 32, 607-608.	3.1	0
42	A surrogate FRAX model for Pakistan. Archives of Osteoporosis, 2021, 16, 34.	2.4	5
43	Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporosis International, 2021, 32, 1601-1608.	3.1	15
44	Epidemiology of hip fracture in Botswana. Archives of Osteoporosis, 2021, 16, 24.	2.4	12
45	The effect on subsequent fracture risk of age, sex, and prior fracture site by recency of prior fracture. Osteoporosis International, 2021, 32, 1547-1555.	3.1	24
46	Summary of the draft federal clinical guidelines for osteoporosis. Osteoporosis and Bone Diseases, 2021, 23, 4-21.	1.4	14
47	Improved prediction of fracture risk leveraging a genome-wide polygenic risk score. Genome Medicine, 2021, 13, 16.	8.2	35
48	A Multicenter Study to Evaluate Harmonization of Assays for C-Terminal Telopeptides of Type I Collagen (ÅY-CTX): A Report from the IFCC-IOF Committee for Bone Metabolism (C-BM). Calcified Tissue International, 2021, 108, 785-797.	3.1	9
49	FRAX-based fracture probabilities in South Africa. Archives of Osteoporosis, 2021, 16, 51.	2.4	10
50	Impact of population-based or targeted BMD interventions on fracture incidence. Osteoporosis International, 2021, 32, 1973-1979.	3.1	5
51	Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and $\hat{1}^2$ -CTX in blood. Clinica Chimica Acta, 2021, 515, 16-20.	1.1	31
52	Short time horizons for fracture prediction tools: time for a rethink. Osteoporosis International, 2021, 32, 1019-1025.	3.1	14
53	An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines. Osteoporosis International, 2021, 32, 1951-1960.	3.1	38
54	FRAX-Based Intervention Thresholds for Osteoporosis Treatment in Ukraine. Journal of Osteoporosis, 2021, 2021, 1-7.	0.5	2

#	ARTICLE	IF	CITATIONS
55	FRAX-based intervention thresholds in eight Eurasian countries: Armenia, Belarus, Georgia, Kazakhstan, the Kyrgyz Republic, Moldova, the Russian Federation, and Uzbekistan. Archives of Osteoporosis, 2021, 16, 87.	2.4	11
56	SCOPE 2021: a new scorecard for osteoporosis in Europe. Archives of Osteoporosis, 2021, 16, 82.	2.4	233
57	A country-specific FRAX model for Botswana. Archives of Osteoporosis, 2021, 16, 90.	2.4	4
58	Ukrainian FRAX version in the male osteoporosis management. BolĚ1, Sustavy, PozvonoĚnik, 2021, 11, 53-61.	0.1	3
59	Calibration of FRAX: A Journey, not a Destination. Calcified Tissue International, 2021, 109, 597-599.	3.1	5
60	Recovery of quality of life is associated with lower mortality 5-year post-fracture: the Australian arm of the International Costs and Utilities Related to Osteoporotic Fractures Study (AusICUROS). Archives of Osteoporosis, 2021, 16, 112.	2.4	7
61	Fracture Risk Assessment and How to Implement a Fracture Liaison Service. Practical Issues in Geriatrics, 2021, , 241-256.	0.8	6
62	The application of FRAX in Saudi Arabia. Archives of Osteoporosis, 2021, 16, 166.	2.4	6
63	Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases, 2021, 24, 4-47.	1.4	43
64	Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. Osteoporosis International, 2020, 31, 67-75.	3.1	25
65	Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporosis International, 2020, 31, 1-12.	3.1	220
66	Reassessment Intervals for Transition From Low to High Fracture Risk Among Adults Older Than 50 Years. JAMA Network Open, 2020, 3, e1918954.	5.9	6
67	Risk for hip fracture before and after total knee replacement in Sweden. Osteoporosis International, 2020, 31, 887-895.	3.1	4
68	Incidence of myocardial infarction and associated mortality varies by latitude and season: findings from a Swedish Registry Study. Journal of Public Health, 2020, 42, e440-e448.	1.8	2
69	Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis. Bone Reports, 2020, 13, 100729.	0.4	14
70	Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs. Drugs, 2020, 80, 1537-1552.	10.9	40
71	Epidemiology of hip fracture and the development of a FRAX model for Uzbekistan. Archives of Osteoporosis, 2020, 15, 119.	2.4	7
72	Use of age-dependent FRAX-based intervention thresholds for Singapore. Archives of Osteoporosis, 2020, 15, 104.	2.4	14

#	ARTICLE	IF	CITATIONS
73	FRAX and ethnicity. <i>Osteoporosis International</i> , 2020, 31, 2063-2067.	3.1	12
74	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1855.	7.4	180
75	Bone densitometry worldwide: a global survey by the ISCD and IOF. <i>Osteoporosis International</i> , 2020, 31, 1779-1786.	3.1	30
76	Fracture risk following high-trauma versus low-trauma fracture: a registry-based cohort study. <i>Osteoporosis International</i> , 2020, 31, 1059-1067.	3.1	52
77	Increased risk for hip fracture after death of a spouse—further support for bereavement frailty?. <i>Osteoporosis International</i> , 2020, 31, 485-492.	3.1	5
78	Alternative and complementary therapies in osteoarthritis and cartilage repair. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 547-560.	2.9	65
79	Quality of life after fragility fracture in the Russian Federation: results from the Russian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (ICUROS). <i>Archives of Osteoporosis</i> , 2020, 15, 37.	2.4	10
80	Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. <i>Osteoporosis International</i> , 2020, 31, 1817-1828.	3.1	53
81	Development of a polygenic risk score to improve screening for fracture risk: A genetic risk prediction study. <i>PLoS Medicine</i> , 2020, 17, e1003152.	8.4	45
82	Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?. <i>Osteoporosis International</i> , 2020, 31, 2271-2286.	3.1	76
83	A surrogate FRAX model for the Kyrgyz Republic. <i>Archives of Osteoporosis</i> , 2020, 15, 68.	2.4	6
84	Loss in DXA-estimated total body lean mass but not fat mass predicts incident major osteoporotic fracture and hip fracture independently from FRAX: a registry-based cohort study. <i>Archives of Osteoporosis</i> , 2020, 15, 96.	2.4	17
85	Epidemiology of osteoporotic fracture in Kazakhstan and development of a country specific FRAX model. <i>Archives of Osteoporosis</i> , 2020, 15, 30.	2.4	21
86	Estimation of Long-Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX- and Virtual Twin-Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials. <i>JBMR Plus</i> , 2020, 4, e10348.	2.7	3
87	Epidemiology of hip fractures in Bulgaria: development of a country-specific FRAX model. <i>Archives of Osteoporosis</i> , 2020, 15, 28.	2.4	4
88	A decade of FRAX: how has it changed the management of osteoporosis?. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 187-196.	2.9	83
89	Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study. <i>Osteoporosis International</i> , 2020, 31, 457-464.	3.1	5
90	Harmonization of commercial assays for PINP; the way forward. <i>Osteoporosis International</i> , 2020, 31, 409-412.	3.1	13

#	ARTICLE	IF	CITATIONS
91	Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study. <i>Osteoporosis International</i> , 2020, 31, 1499-1506.	3.1	17
92	Screening for high fracture risk. <i>Osteoporosis International</i> , 2020, 31, 1179-1180.	3.1	1
93	Fragility fractures in Europe: burden, management and opportunities. <i>Archives of Osteoporosis</i> , 2020, 15, 59.	2.4	369
94	Sarcopenia Definitions as Predictors of Fracture Risk Independent of FRAX®, Falls, and BMD in the Osteoporotic Fractures in Men (MrOS) Study: A Meta-Analysis. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1235-1244.	2.8	33
95	Predictive Value of DXA Appendicular Lean Mass for Incident Fractures, Falls, and Mortality, Independent of Prior Falls, FRAX, and BMD: Findings from the Women's Health Initiative (WHI). <i>Journal of Bone and Mineral Research</i> , 2020, 36, 654-661.	2.8	18
96	Health Service Use and Quality of Life Recovery 12 Months Following Major Osteoporotic Fracture: Latent Class Analyses of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS). <i>Journal of Bone and Mineral Research</i> , 2020, 36, 252-261.	2.8	17
97	Measured height loss predicts incident clinical fractures independently from FRAX: a registry-based cohort study. <i>Osteoporosis International</i> , 2020, 31, 1079-1087.	3.1	16
98	Epidemiology of osteoporotic fracture in Moldova and development of a country-specific FRAX model. <i>Archives of Osteoporosis</i> , 2020, 15, 13.	2.4	20
99	The Effect of Fracture Recency on Observed 10-Year Fracture Probability: A Registry-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 848-855.	2.8	9
100	Potential Adverse Effect of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) on Bisphosphonate Efficacy: An Exploratory Post Hoc Analysis From a Randomized Controlled Trial of Clodronate. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1117-1124.	2.8	2
101	Fracture prediction from self-reported falls in routine clinical practice: a registry-based cohort study. <i>Osteoporosis International</i> , 2019, 30, 2195-2203.	3.1	24
102	East meets West: current practices and policies in the management of musculoskeletal aging. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1351-1373.	2.9	32
103	FRAX-based intervention and assessment thresholds for osteoporosis in Iran. <i>Osteoporosis International</i> , 2019, 30, 2225-2230.	3.1	4
104	Influence of fall environment and fall direction on risk of injury among pre-frail and frail adults. <i>Osteoporosis International</i> , 2019, 30, 2205-2215.	3.1	14
105	Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). <i>Osteoporosis International</i> , 2019, 30, 2155-2165.	3.1	69
106	Assessing the risk of osteoporotic fractures: the Ecuadorian FRAX model. <i>Archives of Osteoporosis</i> , 2019, 14, 93.	2.4	13
107	Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. <i>Oncologist</i> , 2019, 24, 1432-1438.	3.7	10
108	Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. <i>Advances in Therapy</i> , 2019, 36, 2811-2824.	2.9	60

#	ARTICLE	IF	CITATIONS
109	Temporal changes in access to FRAX® in Thailand between 2010 and 2018. Archives of Osteoporosis, 2019, 14, 66.	2.4	10
110	Fracture risk following intermission of osteoporosis therapy. Osteoporosis International, 2019, 30, 1733-1743.	3.1	38
111	Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. Journal of Bone and Mineral Research, 2019, 34, 1428-1435.	2.8	52
112	A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1546-1555.	2.3	25
113	Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review. Calcified Tissue International, 2019, 105, 109-124.	3.1	51
114	Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clinical and Experimental Research, 2019, 31, 905-915.	2.9	47
115	Assessment of Muscle Function and Physical Performance in Daily Clinical Practice. Calcified Tissue International, 2019, 105, 1-14.	3.1	295
116	Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcified Tissue International, 2019, 104, 235-238.	3.1	105
117	Extensive undertreatment of osteoporosis in older Swedish women. Osteoporosis International, 2019, 30, 1297-1305.	3.1	32
118	Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. Archives of Osteoporosis, 2019, 14, 15.	2.4	11
119	Correspondence in response to OSIN-D-18-00831 quantifying imminent risk. Osteoporosis International, 2019, 30, 525-526.	3.1	3
120	Appendicular lean mass and fracture risk assessment: implications for FRAX® and sarcopenia. Osteoporosis International, 2019, 30, 537-539.	3.1	17
121	The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper. British Journal of Haematology, 2019, 185, 410-417.	2.5	10
122	The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease. Kidney International, 2019, 95, 447-454.	5.2	45
123	Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clinical and Experimental Research, 2019, 31, 15-17.	2.9	40
124	Osteoporosis: Treatment Gaps and Health Economics. , 2019, , 288-295.		7
125	Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporosis International, 2019, 30, 45-57.	3.1	67
126	Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 2019, 48, 16-31.	1.6	6,824

#	ARTICLE	IF	CITATIONS
127	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. <i>Osteoporosis International</i> , 2019, 30, 3-44.	3.1	1,020
128	Diagnosis and Clinical Aspects of Osteoporosis. , 2019, , 11-20.		14
129	Ukrainian frax: criteria for diagnostics and treatment of osteoporosis. <i>BolË¹, Sustavy, PozvonoÄnik</i> , 2019, 9, 212-221.	0.1	1
130	Health-related quality of life during the first year after a hip fracture: results of the Mexican arm of the International Cost and Utility Related to Osteoporotic Fractures Study (MexICUROS). <i>Osteoporosis International</i> , 2018, 29, 1147-1154.	3.1	21
131	Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fracturesâ€”A Post Hoc Analysis of the SCOOP Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1020-1026.	2.8	45
132	Epidemiology of hip fracture in Belarus: development of a country-specific FRAX model and its comparison to neighboring country models. <i>Archives of Osteoporosis</i> , 2018, 13, 42.	2.4	16
133	Understanding osteoporotic pain and its pharmacological treatment. <i>Osteoporosis International</i> , 2018, 29, 1477-1491.	3.1	28
134	Bone health assessment in older people with or without muscle health impairment. <i>Osteoporosis International</i> , 2018, 29, 1057-1067.	3.1	33
135	Risk-equivalent T-score adjustment for using lumbar spine trabecular bone score (TBS): the Manitoba BMD registry. <i>Osteoporosis International</i> , 2018, 29, 751-758.	3.1	37
136	Performance of FRAX in clinical practice according to sex and osteoporosis definitions: the Manitoba BMD registry. <i>Osteoporosis International</i> , 2018, 29, 759-767.	3.1	15
137	Pitfalls in the measurement of muscle mass: a need for a reference standard. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 269-278.	7.3	482
138	FRAX-based intervention and assessment thresholds in seven Latin American countries. <i>Osteoporosis International</i> , 2018, 29, 707-715.	3.1	52
139	Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS. <i>Quality of Life Research</i> , 2018, 27, 707-716.	3.1	36
140	Low risk for hip fracture and high risk for hip arthroplasty due to osteoarthritis among Swedish farmers. <i>Osteoporosis International</i> , 2018, 29, 741-749.	3.1	11
141	Does nutrition play a role in the prevention and management of sarcopenia?. <i>Clinical Nutrition</i> , 2018, 37, 1121-1132.	5.0	279
142	Quality of life for up to 18Âmonths after low-energy hip, vertebral, and distal forearm fracturesâ€”results from the ICUROS. <i>Osteoporosis International</i> , 2018, 29, 557-566.	3.1	88
143	Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. <i>Lancet, The</i> , 2018, 391, 741-747.	13.7	206
144	A health economic simulation model for the clinical management of osteoporosis. <i>Osteoporosis International</i> , 2018, 29, 545-555.	3.1	8

#	ARTICLE	IF	CITATIONS
145	Falls Predict Fractures Independently of FRAX Probability: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 510-516.	2.8	61
146	A brief history of FRAX. <i>Archives of Osteoporosis</i> , 2018, 13, 118.	2.4	144
147	In which patients does lumbar spine trabecular bone score (TBS) have the largest effect?. <i>Bone</i> , 2018, 113, 161-168.	2.9	41
148	Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1923-1930.	2.8	104
149	Which Method of Fall Ascertainment Captures the Most Falls in Prefrail and Frail Seniors?. <i>American Journal of Epidemiology</i> , 2018, 187, 2243-2251.	3.4	17
150	Epidemiology of Hip Fractures in Two Regions of Ukraine. <i>Journal of Osteoporosis</i> , 2018, 2018, 1-6.	0.5	9
151	Nutritional Status and Nutritional Treatment Are Related to Outcomes and Mortality in Older Adults with Hip Fracture. <i>Nutrients</i> , 2018, 10, 555.	4.1	186
152	Measures of Physical Performance and Muscle Strength as Predictors of Fracture Risk Independent of FRAX, Falls, and aBMD: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 2150-2157.	2.8	81
153	Benefits and safety of dietary protein for bone health—an expert consensus paper endorsed by the European Society for Clinical and Economical Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation. <i>Osteoporosis International</i> , 2018, 29, 1933-1948.	3.1	98
154	<i>The Authors reply</i>: “Dual energy X-ray absorptiometry: gold standard for muscle mass” by Scafoglieri et al.. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 788-790.	7.3	3
155	Review of the guideline of the American College of Physicians on the treatment of osteoporosis. <i>Osteoporosis International</i> , 2018, 29, 1505-1510.	3.1	26
156	Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (Technology Appraisal 464). <i>Osteoporosis International</i> , 2018, 29, 1511-1513.	3.1	18
157	Characteristics of recurrent fractures. <i>Osteoporosis International</i> , 2018, 29, 1747-1757.	3.1	122
158	Clinical usefulness of bone turnover marker concentrations in osteoporosis. <i>Clinica Chimica Acta</i> , 2017, 467, 34-41.	1.1	96
159	International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. <i>Osteoporosis International</i> , 2017, 28, 767-774.	3.1	113
160	Imminent risk of fracture after fracture. <i>Osteoporosis International</i> , 2017, 28, 775-780.	3.1	275
161	Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. <i>Osteoporosis International</i> , 2017, 28, 1817-1833.	3.1	381
162	Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. <i>Osteoporosis International</i> , 2017, 28, 1507-1529.	3.1	160

#	ARTICLE	IF	CITATIONS
163	Association of Mental Disorders and Related Medication Use With Risk for Major Osteoporotic Fractures. <i>JAMA Psychiatry</i> , 2017, 74, 641.	11.0	60
164	UK clinical guideline for the prevention and treatment of osteoporosis. <i>Archives of Osteoporosis</i> , 2017, 12, 43.	2.4	609
165	Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. <i>Journal of Bone Oncology</i> , 2017, 7, 1-12.	2.4	181
166	The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1625-1631.	2.8	40
167	Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. <i>Osteoporosis International</i> , 2017, 28, 2023-2034.	3.1	126
168	FRAX for fracture prediction shorter and longer than 10 years: the Manitoba BMD registry. <i>Osteoporosis International</i> , 2017, 28, 2557-2564.	3.1	19
169	Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). <i>Endocrine</i> , 2017, 56, 245-261.	2.3	52
170	Clinical Utility of Using Lumbar Spine Trabecular Bone Score to Adjust Fracture Probability: The Manitoba BMD Cohort. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1568-1574.	2.8	52
171	Total Hip Bone Area Affects Fracture Prediction With FRAX® in Canadian White Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4242-4249.	3.6	7
172	Overview of Fracture Prediction Tools. <i>Journal of Clinical Densitometry</i> , 2017, 20, 444-450.	1.2	62
173	FRAX Update. <i>Journal of Clinical Densitometry</i> , 2017, 20, 360-367.	1.2	81
174	FRAX- vs. T-score-based intervention thresholds for osteoporosis. <i>Osteoporosis International</i> , 2017, 28, 3099-3105.	3.1	42
175	Evaluation of clinical risk factors for osteoporosis and applicability of the FRAX tool in Joinville City, Southern Brazil. <i>Archives of Osteoporosis</i> , 2017, 12, 111.	2.4	7
176	Bisphosphonates in osteoporosis: NICE and easy?. <i>Lancet, The</i> , 2017, 390, 2243-2244.	13.7	23
177	Epidemiology of fractures in Armenia: development of a country-specific FRAX model and comparison to its surrogate. <i>Archives of Osteoporosis</i> , 2017, 12, 98.	2.4	24
178	Epidemiology of hip fracture and the development of FRAX in Ukraine. <i>Archives of Osteoporosis</i> , 2017, 12, 53.	2.4	22
179	The role of calcium supplementation in healthy musculoskeletal ageing. <i>Osteoporosis International</i> , 2017, 28, 447-462.	3.1	130
180	How to Implement a Fracture Liaison Service. <i>Practical Issues in Geriatrics</i> , 2017, , 171-184.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Access to fracture risk assessment by FRAX and linked National Osteoporosis Guideline Group (NOGG) guidance in the UK – an analysis of anonymous website activity. <i>Osteoporosis International</i> , 2017, 28, 71-76.	3.1	15
182	Clinical settings in knee osteoarthritis: Pathophysiology guides treatment. <i>Maturitas</i> , 2017, 96, 54-57.	2.4	51
183	Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women. <i>Annals of Internal Medicine</i> , 2017, 167, 902.	3.9	2
184	The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. <i>Oncotarget</i> , 2017, 8, 75646-75663.	1.8	53
185	A comprehensive fracture prevention strategy in older adults: the European Union Geriatric Medicine Society (EUGMS) statement. <i>Aging Clinical and Experimental Research</i> , 2016, 28, 797-803.	2.9	75
186	A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 940-948.	2.8	508
187	Assessment of muscle mass, muscle strength and physical performance in clinical practice: An international survey. <i>European Geriatric Medicine</i> , 2016, 7, 243-246.	2.8	90
188	A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement. <i>European Geriatric Medicine</i> , 2016, 7, 519-525.	2.8	12
189	Longer Duration of Diabetes Strongly Impacts Fracture Risk Assessment: The Manitoba BMD Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4489-4496.	3.6	92
190	Sarcopenia in daily practice: assessment and management. <i>BMC Geriatrics</i> , 2016, 16, 170.	2.7	468
191	A systematic review of intervention thresholds based on FRAX. <i>Archives of Osteoporosis</i> , 2016, 11, 25.	2.4	317
192	Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture. <i>Archives of Osteoporosis</i> , 2016, 11, 37.	2.4	50
193	Direct comparison of FRAXR and a simplified fracture risk assessment tool in routine clinical practice: a registry-based cohort study. <i>Osteoporosis International</i> , 2016, 27, 2689-2695.	3.1	15
194	A comprehensive fracture prevention strategy in older adults: The European Union Geriatric Medicine Society (EUGMS) statement. <i>Journal of Nutrition, Health and Aging</i> , 2016, 20, 647-652.	3.3	65
195	FRAX updates 2016. <i>Current Opinion in Rheumatology</i> , 2016, 28, 433-441.	4.3	37
196	Use of FRAX® in men. <i>Joint Bone Spine</i> , 2016, 83, 477-478.	1.6	3
197	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2016, 28, 1-16.	2.9	22
198	SIGN Guidelines for Scotland: BMD Versus FRAX Versus QFracture. <i>Calcified Tissue International</i> , 2016, 98, 417-425.	3.1	32

#	ARTICLE	IF	CITATIONS
199	Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX® in Portugal. <i>Calcified Tissue International</i> , 2016, 99, 131-141.	3.1	25
200	Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. <i>Drugs and Aging</i> , 2016, 33, 75-85.	2.7	116
201	FRAX predicts incident falls in elderly men: findings from MrOs Sweden. <i>Osteoporosis International</i> , 2016, 27, 267-274.	3.1	41
202	A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis—From evidence-based medicine to the real-life setting. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, S3-S11.	3.4	203
203	Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. <i>Aging Clinical and Experimental Research</i> , 2016, 28, 47-58.	2.9	91
204	Adjusting Hip Fracture Probability in Men and Women Using Hip Axis Length: the Manitoba Bone Density Database. <i>Journal of Clinical Densitometry</i> , 2016, 19, 326-331.	1.2	46
205	Intervention Thresholds and the Diagnosis of Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1747-1753.	2.8	100
206	Can we treat to target in osteoporosis?. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 1-4.	0.3	4
207	The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). <i>Endocrine</i> , 2015, 50, 12-26.	2.3	53
208	Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. <i>Current Medical Research and Opinion</i> , 2015, 31, 1041-1045.	1.9	22
209	Burden of high fracture probability worldwide: secular increases 2010–2040. <i>Osteoporosis International</i> , 2015, 26, 2243-2248.	3.1	382
210	Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. <i>Osteoporosis International</i> , 2015, 26, 2793-2802.	3.1	207
211	Erratum to “The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)” [Maturitas 79 (2014) 122–132]. <i>Maturitas</i> , 2015, 80, 337.	2.4	2
212	Health economic aspects of vertebral augmentation procedures. <i>Osteoporosis International</i> , 2015, 26, 1239-1249.	3.1	11
213	Predictive ability of heel quantitative ultrasound for incident fractures: an individual-level meta-analysis. <i>Osteoporosis International</i> , 2015, 26, 1979-1987.	3.1	74
214	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis. <i>Drugs and Aging</i> , 2015, 32, 179-187.	2.7	82
215	Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. <i>Bone</i> , 2015, 78, 216-224.	2.9	362
216			

#	ARTICLE	IF	CITATIONS
217	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. <i>Drugs and Aging</i> , 2015, 32, 525-535.	2.7	31
218	FRAX and the effect of teriparatide on vertebral and non-vertebral fracture. <i>Osteoporosis International</i> , 2015, 26, 2677-2684.	3.1	35
219	Adjusting Fracture Probability by Trabecular Bone Score. <i>Calcified Tissue International</i> , 2015, 96, 500-509.	3.1	155
220	Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. <i>Osteoporosis International</i> , 2015, 26, 2347-2353.	3.1	34
221	FRAX-based assessment and intervention thresholds – an exploration of thresholds in women aged 50 years and older in the UK. <i>Osteoporosis International</i> , 2015, 26, 2091-2099.	3.1	56
222	Is the Swedish FRAX model appropriate for Swedish immigrants?. <i>Osteoporosis International</i> , 2015, 26, 2617-2622.	3.1	32
223	FRAX and fracture prediction without bone mineral density. <i>Climacteric</i> , 2015, 18, 2-9.	2.4	58
224	Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF Capture the Fracture® Best Practice Framework tool. <i>Osteoporosis International</i> , 2015, 26, 2573-2578.	3.1	99
225	Hip Axis Length Is a FRAX- and Bone Density-Independent Risk Factor for Hip Fracture in Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2063-2070.	3.6	48
226	Incidence of hip fracture in Brazil and the development of a FRAX model. <i>Archives of Osteoporosis</i> , 2015, 10, 224.	2.4	66
227	A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. <i>Pharmacoeconomics</i> , 2015, 33, 205-224.	3.3	84
228	Epidemiological Burden of Postmenopausal Osteoporosis in Italy from 2010 to 2020: Estimations from a Disease Model. <i>Calcified Tissue International</i> , 2014, 95, 419-427.	3.1	20
229	Pre-screening young postmenopausal women for BMD testing. <i>BoneKey Reports</i> , 2014, 3, 544.	2.7	2
230	The Effect of Latitude on the Risk and Seasonal Variation in Hip Fracture in Sweden. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 2217-2223.	2.8	44
231	Republished: Value of biomarkers in osteoarthritis: current status and perspectives. <i>Postgraduate Medical Journal</i> , 2014, 90, 171-178.	1.8	52
232	Can Change in FRAX Score Be Used to “Treat to Target”? A Population-Based Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1074-1080.	2.8	27
233	A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 271-282.	3.4	29
234	Impact of Femoral Neck and Lumbar Spine BMD Discordances on FRAX Probabilities in Women: A Meta-analysis of International Cohorts. <i>Calcified Tissue International</i> , 2014, 95, 428-435.	3.1	52

#	ARTICLE	IF	CITATIONS
235	Worldwide uptake of FRAX. Archives of Osteoporosis, 2014, 9, 166.	2.4	95
236	FRAX provides robust fracture prediction regardless of socioeconomic status. Osteoporosis International, 2014, 25, 61-69.	3.1	28
237	Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporosis International, 2014, 25, 325-337.	3.1	28
238	Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures. Osteoporosis International, 2014, 25, 235-241.	3.1	60
239	An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2014, 44, 253-263.	3.4	414
240	Estimated Lean Mass and Fat Mass Differentially Affect Femoral Bone Density and Strength Index but Are Not FRAX Independent Risk Factors for Fracture. Journal of Bone and Mineral Research, 2014, 29, 2511-2519.	2.8	74
241	Evaluation of the FRAX Model for Hip Fracture Predictions in the Population-based Kuopio Osteoporosis Risk Factor and Prevention Study (OSTPRE). Calcified Tissue International, 2014, 95, 39-45.	3.1	15
242	Cortical Porosity Identifies Women With Osteopenia at Increased Risk for Forearm Fractures. Journal of Bone and Mineral Research, 2014, 29, 1356-1362.	2.8	159
243	Low holotranscobalamin and cobalamins predict incident fractures in elderly men: the MrOS Sweden. Osteoporosis International, 2014, 25, 131-140.	3.1	7
244	Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image. Journal of Bone and Mineral Research, 2014, 29, 518-530.	2.8	617
245	The incidence of a first major osteoporotic fracture in Iceland and implications for FRAX. Osteoporosis International, 2014, 25, 2445-2451.	3.1	29
246	Gaucher Disease and Bone Manifestations. Calcified Tissue International, 2014, 95, 477-494.	3.1	53
247	Goal-directed treatment of osteoporosis in Europe. Osteoporosis International, 2014, 25, 2533-2543.	3.1	61
248	The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas, 2014, 79, 122-132.	2.4	213
249	Management of osteoporosis of the oldest old. Osteoporosis International, 2014, 25, 2507-2529.	3.1	71
250	Epidemiology and economic burden of osteoporosis in Switzerland. Archives of Osteoporosis, 2014, 9, 187.	2.4	81
251	Waning predictive value of serum adiponectin for fracture risk in elderly men: MrOS Sweden. Osteoporosis International, 2014, 25, 1831-1836.	3.1	15
252	Lumbar spine texture enhances 10-year fracture probability assessment. Osteoporosis International, 2014, 25, 2271-2277.	3.1	101

#	ARTICLE	IF	CITATIONS
253	A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture. <i>Calcified Tissue International</i> , 2014, 94, 560-567.	3.1	141
254	Challenges for the Development of Bone-Forming Agents in Europe. <i>Calcified Tissue International</i> , 2014, 94, 469-473.	3.1	19
255	Consensus of Official Position of IOF/ISCD FRAX Initiatives in Asia-Pacific Region. <i>Journal of Clinical Densitometry</i> , 2014, 17, 150-155.	1.2	19
256	The application of health technology assessment in osteoporosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 895-910.	4.7	16
257	The Osteoporosis Treatment Gap. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1926-1928.	2.8	122
258	A Meta-Analysis of the Association of Fracture Risk and Body Mass Index in Women. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 223-233.	2.8	388
259	EPIDEMIOLOGY OF OSTEOPOROTIC FRACTURES IN THE RUSSIAN FEDERATION AND THE RUSSIAN MODEL OF FRAX. <i>Osteoporosis and Bone Diseases</i> , 2014, 17, 3-8.	1.4	9
260	Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF. <i>Osteoporosis International</i> , 2013, 24, 2763-2764.	3.1	121
261	Intervention thresholds for denosumab in the UK using a FRAX [®] -based cost-effectiveness analysis. <i>Osteoporosis International</i> , 2013, 24, 1491-1502.	3.1	35
262	Updated fracture incidence rates for the Italian version of FRAX [®] . <i>Osteoporosis International</i> , 2013, 24, 859-866.	3.1	33
263	Tools in the Assessment of Sarcopenia. <i>Calcified Tissue International</i> , 2013, 93, 201-210.	3.1	197
264	Health Technology Assessment in Osteoporosis. <i>Calcified Tissue International</i> , 2013, 93, 1-14.	3.1	39
265	Incidence of Hip Fracture in Barranquilla, Colombia, and the Development of a Colombian FRAX Model. <i>Calcified Tissue International</i> , 2013, 93, 15-22.	3.1	27
266	Incidence of Hip Fracture in Romania and the Development of a Romanian FRAX Model. <i>Calcified Tissue International</i> , 2013, 92, 429-436.	3.1	38
267	Assessing the Impact of Osteoporosis on the Burden of Hip Fractures. <i>Calcified Tissue International</i> , 2013, 92, 42-49.	3.1	104
268	Fracture Risk Assessment. , 2013, , 1611-1637.		5
269	Quality of Life in Sarcopenia and Frailty. <i>Calcified Tissue International</i> , 2013, 93, 101-120.	3.1	310
270	Direct comparison of eight national FRAX [®] tools for fracture prediction and treatment qualification in Canadian women. <i>Archives of Osteoporosis</i> , 2013, 8, 145.	2.4	24

#	ARTICLE	IF	CITATIONS
271	The Resource Use Related to Hip Fractures Based on Data from ICUROS. Value in Health, 2013, 16, A573-A574.	0.3	2
272	Erratum to "Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013" [Maturitas 75 (2013) 392-396]. Maturitas, 2013, 76, 387.	2.4	1
273	Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2013, 43, 303-313.	3.4	239
274	FRAX-based intervention and assessment thresholds for osteoporosis in Romania. Archives of Osteoporosis, 2013, 8, 164.	2.4	11
275	Osteoporosis in the European Union: a compendium of country-specific reports. Archives of Osteoporosis, 2013, 8, 137.	2.4	561
276	Osteoporosis in the European Union: medical management, epidemiology and economic burden. Archives of Osteoporosis, 2013, 8, 136.	2.4	1,932
277	SCOPE: a scorecard for osteoporosis in Europe. Archives of Osteoporosis, 2013, 8, 144.	2.4	125
278	Development and application of FRAX in the management of osteoporosis in Ireland. Archives of Osteoporosis, 2013, 8, 146.	2.4	12
279	How to define responders in osteoarthritis. Current Medical Research and Opinion, 2013, 29, 719-729.	1.9	75
280	Osteoporosis risk in Type 2 diabetes patients. Expert Review of Endocrinology and Metabolism, 2013, 8, 423-425.	2.4	5
281	Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Current Medical Research and Opinion, 2013, 29, 305-313.	1.9	266
282	Pitfalls in the external validation of FRAX: response to Bolland et al.. Osteoporosis International, 2013, 24, 391-392.	3.1	5
283	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 2013, 24, 23-57.	3.1	1,560
284	Treatment of osteoporosis in men. Bone, 2013, 53, 134-144.	2.9	84
285	Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas, 2013, 75, 392-396.	2.4	264
286	Selection of Women Aged 50-64 Yr for Bone Density Measurement. Journal of Clinical Densitometry, 2013, 16, 570-578.	1.2	18
287	The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS) quality of life during the first 4 months after fracture. Osteoporosis International, 2013, 24, 811-823.	3.1	114
288	What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis?. Annals of the Rheumatic Diseases, 2013, 72, 1594-1604.	0.9	91

#	ARTICLE	IF	CITATIONS
289	Inflammatory bowel disease and the risk of fracture after controlling for FRAX. Journal of Bone and Mineral Research, 2013, 28, 1007-1013.	2.8	27
290	Commentary on guidelines on postmenopausal osteoporosis - Indian Menopause Society. Journal of Mid-Life Health, 2013, 4, 129-31.	0.6	5
291	FRAX updates 2012. Current Opinion in Rheumatology, 2012, 24, 554-560.	4.3	43
292	High serum adiponectin predicts incident fractures in elderly men: Osteoporotic fractures in men (MrOS) Sweden. Journal of Bone and Mineral Research, 2012, 27, 1390-1396.	2.8	49
293	A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2224-2260.	13.7	9,397
294	Type 2 diabetes and bone. Journal of Bone and Mineral Research, 2012, 27, 2231-2237.	2.8	304
295	Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporosis International, 2012, 23, 2579-2589.	3.1	66
296	A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporosis International, 2012, 23, 2507-2515.	3.1	51
297	FRAX® probabilities and risk of major osteoporotic fracture in France. Osteoporosis International, 2012, 23, 2321-2327.	3.1	26
298	A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporosis International, 2012, 23, 2257-2276.	3.1	291
299	A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporosis International, 2012, 23, 2239-2256.	3.1	1,048
300	Variations in latitude may or may not explain the worldwide variation in hip fracture incidence. Osteoporosis International, 2012, 23, 2401-2402.	3.1	3
301	Treatment failure in osteoporosis. Osteoporosis International, 2012, 23, 2769-2774.	3.1	177
302	Fracture risk assessment. Clinical Biochemistry, 2012, 45, 887-893.	1.9	44
303	Antidepressant medications and osteoporosis. Bone, 2012, 51, 606-613.	2.9	144
304	Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Archives of Osteoporosis, 2012, 7, 67-73.	2.4	73
305	The distribution of FRAX®-based probabilities in women from Japan. Journal of Bone and Mineral Metabolism, 2012, 30, 700-705.	2.7	31
306	An appendix to the 2012 IOFâ€“ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Archives of Osteoporosis, 2012, 7, 25-30.	2.4	35

#	ARTICLE	IF	CITATIONS
307	A global representation of vitamin D status in healthy populations. Archives of Osteoporosis, 2012, 7, 155-172.	2.4	260
308	Burden of postmenopausal osteoporosis in Germany: estimations from a disease model. Archives of Osteoporosis, 2012, 7, 209-218.	2.4	16
309	The impact of a FRAX-based intervention threshold in Turkey: the FRAX-TURK study. Archives of Osteoporosis, 2012, 7, 229-235.	2.4	28
310	Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model. Archives of Osteoporosis, 2012, 7, 237-246.	2.4	30
311	Management of Glucocorticoid-Induced Osteoporosis. Calcified Tissue International, 2012, 91, 225-243.	3.1	77
312	Potential Extensions of the US FRAX Algorithm. Journal of Osteoporosis, 2012, 2012, 1-8.	0.5	18
313	Does osteoporosis therapy invalidate FRAX for fracture prediction?. Journal of Bone and Mineral Research, 2012, 27, 1243-1251.	2.8	105
314	Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. Journal of Bone and Mineral Research, 2012, 27, 1480-1486.	2.8	126
315	FRAX underestimates fracture risk in patients with diabetes. Journal of Bone and Mineral Research, 2012, 27, 301-308.	2.8	307
316	Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Current Medical Research and Opinion, 2012, 28, 475-491.	1.9	39
317	Comment on: cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporosis International, 2012, 23, 2063-2065.	3.1	4
318	Frailty and sarcopenia: definitions and outcome parameters. Osteoporosis International, 2012, 23, 1839-1848.	3.1	258
319	Hip Fracture Incidence from 1981 to 2009 in the Czech Republic as a Basis of the Country-Specific FRAX Model. Calcified Tissue International, 2012, 90, 365-372.	3.1	19
320	Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporosis International, 2012, 23, 193-199.	3.1	6
321	High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporosis International, 2012, 23, 391-397.	3.1	89
322	Incidence of hip fracture and prevalence of osteoporosis in Turkey: the FRACTURK study. Osteoporosis International, 2012, 23, 949-955.	3.1	124
323	The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008. Osteoporosis International, 2012, 23, 811-820.	3.1	83
324	Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporosis International, 2012, 23, 75-85.	3.1	102

#	ARTICLE	IF	CITATIONS
325	A reappraisal of generic bisphosphonates in osteoporosis. <i>Osteoporosis International</i> , 2012, 23, 213-221.	3.1	62
326	A comparative study of using non-hip bone density inputs with FRAX®. <i>Osteoporosis International</i> , 2012, 23, 853-860.	3.1	17
327	Pitfalls in the external validation of FRAX. <i>Osteoporosis International</i> , 2012, 23, 423-431.	3.1	95
328	Calibration of FRAX® 3.1 to the Dutch population with data on the epidemiology of hip fractures. <i>Osteoporosis International</i> , 2012, 23, 861-869.	3.1	44
329	A comparison of case-finding strategies in the UK for the management of hip fractures. <i>Osteoporosis International</i> , 2012, 23, 907-915.	3.1	47
330	FRAX® with and without Bone Mineral Density. <i>Calcified Tissue International</i> , 2012, 90, 1-13.	3.1	173
331	FRAX - A NEW TOOL FOR THE ASSESSMENT OF FRACTURE RISK: APPLICATION IN CLINICAL PRACTICE AND THRESHOLDS FOR INTERVENTION. <i>Osteoporosis and Bone Diseases</i> , 2012, 15, 38-44.	1.4	2
332	Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. <i>Journal of Clinical Densitometry</i> , 2011, 14, 171-180.	1.2	82
333	Official Positions for FRAX® Bone Mineral Density and FRAX® Simplification. <i>Journal of Clinical Densitometry</i> , 2011, 14, 226-236.	1.2	45
334	FRAX® Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. <i>Journal of Clinical Densitometry</i> , 2011, 14, 223-225.	1.2	19
335	Standardising biochemical assessment of bone turnover in osteoporosis. <i>Clinical Biochemistry</i> , 2011, 44, 1033-1034.	1.9	12
336	A FRAX® model for the assessment of fracture probability in Belgium. <i>Osteoporosis International</i> , 2011, 22, 453-461.	3.1	53
337	Hip fracture risk in older US adults by treatment eligibility status based on new National Osteoporosis Foundation guidance. <i>Osteoporosis International</i> , 2011, 22, 541-549.	3.1	23
338	Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. <i>Osteoporosis International</i> , 2011, 22, 955-965.	3.1	28
339	Low bone mineral density is associated with increased mortality in elderly men: MrOS Sweden. <i>Osteoporosis International</i> , 2011, 22, 1411-1418.	3.1	31
340	Development and validation of a disease model for postmenopausal osteoporosis. <i>Osteoporosis International</i> , 2011, 22, 771-780.	3.1	17
341	Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. <i>Osteoporosis International</i> , 2011, 22, 967-982.	3.1	106
342	Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. <i>Osteoporosis International</i> , 2011, 22, 373-390.	3.1	220

#	ARTICLE	IF	CITATIONS
343	Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporosis International, 2011, 22, 839-847.	3.1	131
344	Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporosis International, 2011, 22, 817-827.	3.1	144
345	Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporosis International, 2011, 22, 829-837.	3.1	160
346	A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®. Osteoporosis International, 2011, 22, 2347-2355.	3.1	82
347	Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican institute of social security. Osteoporosis International, 2011, 22, 2359-2364.	3.1	49
348	Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis International, 2011, 22, 391-420.	3.1	893
349	Evaluation of FRAX to characterise fracture risk in Poland. Osteoporosis International, 2011, 22, 2507-2512.	3.1	21
350	Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporosis International, 2011, 22, 809-816.	3.1	248
351	Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporosis International, 2011, 22, 1277-1288.	3.1	715
352	Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporosis International, 2011, 22, 2789-2798.	3.1	109
353	Breaking the fragility fracture cycle. Osteoporosis International, 2011, 22, 2049-2050.	3.1	37
354	Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporosis International, 2011, 22, 2565-2573.	3.1	55
355	Interpretation and use of FRAX in clinical practice. Osteoporosis International, 2011, 22, 2395-2411.	3.1	450
356	Adverse Reactions and Drug-Drug Interactions in the Management of Women with Postmenopausal Osteoporosis. Calcified Tissue International, 2011, 89, 91-104.	3.1	170
357	Osteoporosis: burden, health care provision and opportunities in the EU. Archives of Osteoporosis, 2011, 6, 59-155.	2.4	459
358	Epidemiological burden of postmenopausal osteoporosis in the UK from 2010 to 2021: estimations from a disease model. Archives of Osteoporosis, 2011, 6, 179-188.	2.4	69
359	Milk intake and risk of hip fracture in men and women: A meta-analysis of prospective cohort studies. Journal of Bone and Mineral Research, 2011, 26, 833-839.	2.8	119
360	International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1271-1274.	2.3	274

#	ARTICLE	IF	CITATIONS
361	Recommendations for bone marker standards in osteoporosis: what, why and where to now?. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 91-92.	1.6	8
362	The application of FRAX® to determine intervention thresholds in osteoporosis treatment in Poland. <i>Polish Archives of Internal Medicine</i> , 2011, 121, 148-155.	0.4	7
363	The application of FRAX® to determine intervention thresholds in osteoporosis treatment in Poland. , 2011, 121, 148-55.		7
364	Smoking predicts incident fractures in elderly men: Mr OS Sweden. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 1010-1016.	2.8	55
365	Validation of the IOF quality of life questionnaire for patients with wrist fracture. <i>Osteoporosis International</i> , 2010, 21, 61-70.	3.1	20
366	The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. <i>Osteoporosis International</i> , 2010, 21, 339-349.	3.1	23
367	FRAX® assessment of osteoporotic fracture probability in Switzerland. <i>Osteoporosis International</i> , 2010, 21, 381-389.	3.1	106
368	The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®. <i>Osteoporosis International</i> , 2010, 21, 495-505.	3.1	46
369	The effects of a FRAX® revision for the USA. <i>Osteoporosis International</i> , 2010, 21, 35-40.	3.1	89
370	The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. <i>Osteoporosis International</i> , 2010, 21, 41-52.	3.1	98
371	Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study. <i>Osteoporosis International</i> , 2010, 21, 53-60.	3.1	62
372	The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). <i>Osteoporosis International</i> , 2010, 21, 713-722.	3.1	10
373	Development and use of FRAX® in osteoporosis. <i>Osteoporosis International</i> , 2010, 21, 407-413.	3.1	320
374	An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. <i>Archives of Osteoporosis</i> , 2010, 5, 19-48.	2.4	18
375	Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 2350-2358.	2.8	243
376	New osteoporosis guidelines for Canada. <i>Cmaj</i> , 2010, 182, 1829-1830.	2.0	12
377	FRAX® and its applications in health economicsâ€”Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. <i>Bone</i> , 2010, 47, 430-437.	2.9	34
378	A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX®. <i>Bone</i> , 2010, 47, 729-735.	2.9	93

#	ARTICLE	IF	CITATIONS
379	Diagnostic Thresholds for Osteoporosis in Men. , 2010, , 605-611.		3
380	Cost-Effectiveness of Hormone Therapy in the United States. Journal of Women's Health, 2009, 18, 1669-1677.	3.3	25
381	Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK. Menopause International, 2009, 15, 19-25.	1.6	13
382	How to decide who to treat. Best Practice and Research in Clinical Rheumatology, 2009, 23, 711-726.	3.3	23
383	From relative risk to absolute fracture risk calculation: The FRAX algorithm. Current Osteoporosis Reports, 2009, 7, 77-83.	3.6	130
384	Incorporating adherence into health economic modelling of osteoporosis. Osteoporosis International, 2009, 20, 23-34.	3.1	63
385	Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporosis International, 2009, 20, 1131-1140.	3.1	171
386	Ten-year fracture probability identifies women who will benefit from clodronate therapy"additional results from a double-blind, placebo-controlled randomised study. Osteoporosis International, 2009, 20, 811-817.	3.1	134
387	The incidence and risk of hip fracture in Poland. Osteoporosis International, 2009, 20, 1363-1367.	3.1	41
388	An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporosis International, 2009, 20, 853-868.	3.1	118
389	BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporosis International, 2009, 20, 1675-1682.	3.1	121
390	Ten-year fracture probability in Hong Kong Southern Chinese according to age and BMD femoral neck T-scores. Osteoporosis International, 2009, 20, 1939-1945.	3.1	43
391	Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate. Osteoporosis International, 2009, 20, 2055-2061.	3.1	34
392	Assessment of fracture risk. European Journal of Radiology, 2009, 71, 392-397.	2.6	109
393	FRAX® and its applications to clinical practice. Bone, 2009, 44, 734-743.	2.9	605
394	Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®. Bone, 2009, 44, 1049-1054.	2.9	147
395	Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas, 2009, 62, 105-108.	2.4	346
396	Approaches to the targeting of treatment for osteoporosis. Nature Reviews Rheumatology, 2009, 5, 425-431.	8.0	39

#	ARTICLE	IF	CITATIONS
397	The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden. <i>Osteoporosis International</i> , 2008, 19, 819-827.	3.1	18
398	Expressing fracture risk. <i>Osteoporosis International</i> , 2008, 19, 593-594.	3.1	3
399	FRAX [®] and the assessment of fracture probability in men and women from the UK. <i>Osteoporosis International</i> , 2008, 19, 385-397.	3.1	2,017
400	Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX [®]). <i>Osteoporosis International</i> , 2008, 19, 429-435.	3.1	163
401	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. <i>Osteoporosis International</i> , 2008, 19, 399-428.	3.1	792
402	NICE continues to muddy the waters of osteoporosis. <i>Osteoporosis International</i> , 2008, 19, 1105-1107.	3.1	4
403	Case finding for the management of osteoporosis with FRAX [®] assessment and intervention thresholds for the UK. <i>Osteoporosis International</i> , 2008, 19, 1395-1408.	3.1	520
404	Assessment of the 10-Year Probability of Osteoporotic Hip Fracture Combining Clinical Risk Factors and Heel Bone Ultrasound: The EPISEM Prospective Cohort of 12,958 Elderly Women. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1045-1051.	2.8	66
405	Vertebral Fracture Assessment (VFA) With a Densitometer Predicts Future Fractures in Elderly Women Unselected for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1561-1568.	2.8	89
406	Health economics of osteoporosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 885-900.	4.7	25
407	Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK—Results based on the Women's Health Initiative randomised controlled trial. <i>Bone</i> , 2008, 42, 294-306.	2.9	31
408	The cost-effectiveness of alendronate in the management of osteoporosis. <i>Bone</i> , 2008, 42, 4-15.	2.9	136
409	A reference standard for the description of osteoporosis. <i>Bone</i> , 2008, 42, 467-475.	2.9	929
410	Modelling cost-effectiveness in osteoporosis. <i>Bone</i> , 2008, 43, 215-216.	2.9	5
411	Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. <i>Bone</i> , 2008, 43, 343-347.	2.9	57
412	Critical Issues in Translational and Clinical Research for the Study of New Technologies to Enhance Bone Repair. <i>Journal of Bone and Joint Surgery - Series A</i> , 2008, 90, 43-47.	3.0	20
413	FRAX [®] and the assessment of fracture probability: An introduction. <i>IBMS BoneKEy</i> , 2008, 5, 114-117.	0.0	0
414	European guidance for the diagnosis and management of osteoporosis in postmenopausal women—what is the current message for clinical practice?. , 2008, 118, 538-40.		12

#	ARTICLE	IF	CITATIONS
415	The Cost-Effectiveness of Bisphosphonates in Postmenopausal Women Based on Individual Long-Term Fracture Risks. <i>Value in Health</i> , 2007, 10, 348-357.	0.3	28
416	Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. <i>Osteoporosis International</i> , 2007, 18, 333-337.	3.1	99
417	Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model. <i>Osteoporosis International</i> , 2007, 18, 9-23.	3.1	169
418	The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. <i>Osteoporosis International</i> , 2007, 18, 1033-1046.	3.1	1,017
419	Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. <i>Osteoporosis International</i> , 2007, 18, 1047-1061.	3.1	92
420	Adherence to treatment of osteoporosis: a need for study. <i>Osteoporosis International</i> , 2007, 18, 1311-1317.	3.1	103
421	Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. <i>Health Technology Assessment</i> , 2007, 11, iii-iv, ix-xi, 1-231.	2.8	124
422	Olof Johnell. <i>Journal of Clinical Densitometry</i> , 2006, 9, 387.	1.2	0
423	The hospitalisation costs and out-patient costs of fragility fractures. <i>Women's Health Medicine</i> , 2006, 3, 149-151.	0.0	34
424	Preservation of thoracic spine microarchitecture by alendronate: Comparison of histology and microCT. <i>Bone</i> , 2006, 38, 444-449.	2.9	25
425	Cost Implications of Bisphosphonates. , 2006, , 415-426.		0
426	Prevention of Bone Loss. , 2006, , 399-414.		0
427	Clodronate Reduces the Incidence of Fractures in Community-Dwelling Elderly Women Unselected for Osteoporosis: Results of a Double-Blind, Placebo-Controlled Randomized Study. <i>Journal of Bone and Mineral Research</i> , 2006, 22, 135-141.	2.8	180
428	The use of multiple sites for the diagnosis of osteoporosis. <i>Osteoporosis International</i> , 2006, 17, 527-534.	3.1	91
429	Whom to treat? The contribution of vertebral X-rays to risk-based algorithms for fracture prediction. Results from the European Prospective Osteoporosis Study. <i>Osteoporosis International</i> , 2006, 17, 1369-1381.	3.1	34
430	The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. <i>Osteoporosis International</i> , 2006, 17, 996-1007.	3.1	54
431	At what hip fracture risk is it cost-effective to treat?. <i>Osteoporosis International</i> , 2006, 17, 1459-1471.	3.1	117
432	Bone fragility in men - where are we?. <i>Osteoporosis International</i> , 2006, 17, 1577-1583.	3.1	97

#	ARTICLE	IF	CITATIONS
433	An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. <i>Osteoporosis International</i> , 2006, 17, 1726-1733.	3.1	3,564
434	An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting. <i>Osteoporosis International</i> , 2006, 17, 1781-1793.	3.1	66
435	A simple clinical score for estimating the long-term risk of fracture in post-menopausal women. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 673-682.	0.5	43
436	Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: Results based on the Women's Health Initiative randomized controlled trial. <i>International Journal of Technology Assessment in Health Care</i> , 2005, 21, 433-441.	0.5	28
437	Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women. <i>Journal of the Operational Research Society</i> , 2005, 56, 214-221.	3.4	22
438	Predictive Value of BMD for Hip and Other Fractures. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1185-1194.	2.8	1,213
439	Potential Impact of Osteoporosis Treatment on Hip Fracture Trends. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 895-897.	2.8	36
440	Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. <i>Osteoporosis International</i> , 2005, 16, 6-14.	3.1	109
441	Smoking and fracture risk: a meta-analysis. <i>Osteoporosis International</i> , 2005, 16, 155-162.	3.1	755
442	The burden of hospitalised fractures in Sweden. <i>Osteoporosis International</i> , 2005, 16, 222-228.	3.1	92
443	Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. <i>Osteoporosis International</i> , 2005, 16, 15-25.	3.1	65
444	The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. <i>Osteoporosis International</i> , 2005, 16, 313-318.	3.1	116
445	Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. <i>Osteoporosis International</i> , 2005, 16, 475-482.	3.1	92
446	Epidemiology of osteoporotic fractures. <i>Osteoporosis International</i> , 2005, 16, S3-S7.	3.1	948
447	Alcohol intake as a risk factor for fracture. <i>Osteoporosis International</i> , 2005, 16, 737-742.	3.1	473
448	A meta-analysis of milk intake and fracture risk: low utility for case finding. <i>Osteoporosis International</i> , 2005, 16, 799-804.	3.1	123
449	Assessment of fracture risk. <i>Osteoporosis International</i> , 2005, 16, 581-589.	3.1	1,052
450	Ten-year probabilities of clinical vertebral fractures according to phalangeal quantitative ultrasonography. <i>Osteoporosis International</i> , 2005, 16, 1065-1070.	3.1	37

#	ARTICLE	IF	CITATIONS
451	Requirements for DXA for the management of osteoporosis in Europe. <i>Osteoporosis International</i> , 2005, 16, 229-238.	3.1	398
452	The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry. <i>Osteoporosis International</i> , 2005, 16, 456-459.	3.1	28
453	Body mass index as a predictor of fracture risk: A meta-analysis. <i>Osteoporosis International</i> , 2005, 16, 1330-1338.	3.1	1,292
454	Incidence rates and life-time risk of hip fractures in Mexicans over 50 years of age: a population-based study. <i>Osteoporosis International</i> , 2005, 16, 2025-2030.	3.1	72
455	The Perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry. <i>Journal of Clinical Densitometry</i> , 2005, 8, 145-147.	1.2	20
456	Intervention thresholds for osteoporosis in the UK. <i>Bone</i> , 2005, 36, 22-32.	2.9	113
457	Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double-Blind, Placebo-Controlled 3-Year Study. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 728-736.	2.8	114
458	A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 893-899.	2.8	666
459	Associations Between Baseline Risk Factors and Vertebral Fracture Risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 764-772.	2.8	104
460	Risk Factors for Incident Vertebral Fractures in Men and Women: The Rotterdam Study. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1172-1180.	2.8	160
461	Evidence From Data Searches and Life-Table Analyses for Gender-Related Differences in Absolute Risk of Hip Fracture After Colles' or Spine Fracture: Colles' Fracture as an Early and Sensitive Marker of Skeletal Fragility in White Men. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1933-1944.	2.8	87
462	Optimization of BMD Measurements to Identify High Risk Groups for Treatment-A Test Analysis. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 906-913.	2.8	130
463	The risk and burden of vertebral fractures in Sweden. <i>Osteoporosis International</i> , 2004, 15, 20-26.	3.1	222
464	Mortality after osteoporotic fractures. <i>Osteoporosis International</i> , 2004, 15, 38-42.	3.1	706
465	Fracture risk following an osteoporotic fracture. <i>Osteoporosis International</i> , 2004, 15, 175-179.	3.1	377
466	Excess mortality after hospitalisation for vertebral fracture. <i>Osteoporosis International</i> , 2004, 15, 108-112.	3.1	250
467	Health-related quality of life and radiographic vertebral fracture. <i>Osteoporosis International</i> , 2004, 15, 113-119.	3.1	161
468	Back pain, disability, and radiographic vertebral fracture in European women: a prospective study. <i>Osteoporosis International</i> , 2004, 15, 760-765.	3.1	106

#	ARTICLE	IF	CITATIONS
469	An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. <i>Osteoporosis International</i> , 2004, 15, 897-902.	3.1	752
470	Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. <i>Osteoporosis International</i> , 2004, 15, 862-871.	3.1	76
471	Epidemiology of Osteoporosis and Fracture in Men. <i>Calcified Tissue International</i> , 2004, 75, 90-99.	3.1	84
472	Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden. <i>Pharmacoeconomics</i> , 2004, 22, 1153-1165.	3.3	46
473	Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. <i>Bone</i> , 2004, 34, 728-735.	2.9	161
474	A meta-analysis of previous fracture and subsequent fracture risk. <i>Bone</i> , 2004, 35, 375-382.	2.9	1,052
475	A family history of fracture and fracture risk: a meta-analysis. <i>Bone</i> , 2004, 35, 1029-1037.	2.9	344
476	Idiopathic Hyperphosphatasia and TNFRSF11B Mutations: Relationships Between Phenotype and Genotype. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 2095-2104.	2.8	113
477	Study Design in Osteoporosis: A European Perspective. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 1133-1138.	2.8	19
478	Association Between Vertebral Fracture and Increased Mortality in Osteoporotic Patients. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 1254-1260.	2.8	220
479	Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). <i>Osteoporosis International</i> , 2003, 14, 19-26.	3.1	251
480	Cost-equivalence of different osteoporotic fractures. <i>Osteoporosis International</i> , 2003, 14, 383-388.	3.1	165
481	Extended Safety Profile of Oral Clodronate After Long-Term Use in Primary Breast Cancer Patients. <i>Drug Safety</i> , 2003, 26, 661-671.	3.2	45
482	The components of excess mortality after hip fracture. <i>Bone</i> , 2003, 32, 468-473.	2.9	462
483	Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene Evaluation trial ¹¹ Eli Lilly and Company (Indianapolis, IN) sponsored the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.. <i>Bone</i> , 2003, 33, 293-300.	2.9	168
484	Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). <i>Bone</i> , 2003, 33, 505-513.	2.9	192
485	Osteoporosis management by geriatricians in the UK. <i>Age and Ageing</i> , 2003, 32, 553-553.	1.6	3
486	Performance of clinical referral criteria for bone densitometry in patients under 65 years of age assessed by spine bone mineral density. <i>Postgraduate Medical Journal</i> , 2003, 79, 581-584.	1.8	7

#	ARTICLE	IF	CITATIONS
487	Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 3219-3224.	1.6	362
488	Diagnosis of osteoporosis and assessment of fracture risk. <i>Lancet</i> , The, 2002, 359, 1929-1936.	13.7	1,763
489	Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. <i>Bone</i> , 2002, 30, 251-258.	2.9	180
490	Optimal age for preventing osteoporosis after menopause depends on effects of stopping treatment. <i>Bone</i> , 2002, 30, 754-758.	2.9	9
491	Calcitonin in osteoporosis. <i>Bone</i> , 2002, 30, 65-66.	2.9	7
492	Intervention thresholds for osteoporosis. <i>Bone</i> , 2002, 31, 26-31.	2.9	74
493	Falls explain between-center differences in the incidence of limb fracture across Europe. <i>Bone</i> , 2002, 31, 712-717.	2.9	47
494	Uncertain Future of Trials in Osteoporosis. <i>Osteoporosis International</i> , 2002, 13, 443-449.	3.1	45
495	Biochemical Indices of Bone Turnover and the Assessment of Fracture Probability. <i>Osteoporosis International</i> , 2002, 13, 523-526.	3.1	181
496	A New Approach to the Development of Assessment Guidelines for Osteoporosis. <i>Osteoporosis International</i> , 2002, 13, 527-536.	3.1	294
497	Incidence of Limb Fracture across Europe: Results from the European Prospective Osteoporosis Study (EPOS). <i>Osteoporosis International</i> , 2002, 13, 565-571.	3.1	191
498	Economic Evaluation of Interventions for Osteoporosis. <i>Osteoporosis International</i> , 2002, 13, 765-767.	3.1	50
499	A Systematic Review of Health State Utility Values for Osteoporosis-Related Conditions. <i>Osteoporosis International</i> , 2002, 13, 768-776.	3.1	95
500	Defining Incident Vertebral Deformities in Population Studies: A Comparison of Morphometric Criteria. <i>Osteoporosis International</i> , 2002, 13, 809-815.	3.1	42
501	Models for Assessing the Cost-Effectiveness of the Treatment and Prevention of Osteoporosis. <i>Osteoporosis International</i> , 2002, 13, 841-857.	3.1	56
502	Incidence of Vertebral Fracture in Europe: Results From the European Prospective Osteoporosis Study (EPOS). <i>Journal of Bone and Mineral Research</i> , 2002, 17, 716-724.	2.8	551
503	International Variations in Hip Fracture Probabilities: Implications for Risk Assessment. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 1237-1244.	2.8	511
504	Neurological Complications of Paget's Disease. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2002, 1, 135-144.	0.8	11

#	ARTICLE	IF	CITATIONS
505	Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment, 2002, 6, 1-146.	2.8	197
506	Assessing the risk of vertebral osteoporosis. Singapore Medical Journal, 2002, 43, 100-5.	0.6	7
507	The Clinical and Cost Considerations of Bisphosphonates in Preventing Bone Complications in Patients with Metastatic Breast Cancer or Multiple Myeloma. Drugs, 2001, 61, 1253-1274.	10.9	36
508	Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone, 2001, 28, 310-315.	2.9	47
509	Targeting of hormone replacement therapy immediately after menopause. Bone, 2001, 28, 440-445.	2.9	9
510	Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic Thresholds. Osteoporosis International, 2001, 12, 989-995.	3.1	714
511	Cost-Effectiveness of Preventing Hip Fracture in the General Female Population. Osteoporosis International, 2001, 12, 356-361.	3.1	59
512	The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds. Osteoporosis International, 2001, 12, 417-427.	3.1	603
513	Acute and Long-Term Increase in Fracture Risk after Hospitalization for Vertebral Fracture. Osteoporosis International, 2001, 12, 207-214.	3.1	128
514	Prevalent Vertebral Deformity Predicts Incident Hip though not distal Forearm Fracture: Results from the European Prospective Osteoporosis Study. Osteoporosis International, 2001, 12, 85-90.	3.1	159
515	Diagnosis of Osteoporosis and Fracture Threshold in Men. Calcified Tissue International, 2001, 69, 218-221.	3.1	79
516	Studies of Bone Density, Quantitative Ultrasound, and Vertebral Fractures in Relation to Collagen Type I Alpha 1 Alleles in Elderly Women. Calcified Tissue International, 2001, 68, 348-351.	3.1	36
517	Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. British Journal of Haematology, 2001, 113, 1035-1043.	2.5	160
518	Atypical familial Paget's disease of bone. Joint Bone Spine, 2001, 68, 257-261.	1.6	4
519	Acute and Long-Term Increase in Fracture Risk After Hospitalization for Stroke. Stroke, 2001, 32, 702-706.	2.0	231
520	Bisphosphonates in multiple myeloma. Cancer, 2000, 88, 3022-3032.	4.1	46
521	Insufficiency fracture of the calcaneum: an unusual cause of heel pain. Foot, 2000, 10, 169-171.	1.1	1
522	Health-Related Quality of Life in Postmenopausal Women With Low BMD With or Without Prevalent Vertebral Fractures. Journal of Bone and Mineral Research, 2000, 15, 1384-1392.	2.8	432

#	ARTICLE	IF	CITATIONS
523	An update on the diagnosis of osteoporosis. <i>Current Rheumatology Reports</i> , 2000, 2, 62-66.	4.7	39
524	An Update on the Diagnosis and Assessment of Osteoporosis with Densitometry. <i>Osteoporosis International</i> , 2000, 11, 192-202.	3.1	799
525	Metacarpal Morphometry Using a Semi-automated Technique in the Assessment of Osteoporosis and Vertebral Fracture Risk. <i>Osteoporosis International</i> , 2000, 11, 953-958.	3.1	26
526	Long-Term Risk of Osteoporotic Fracture in Malmö. <i>Osteoporosis International</i> , 2000, 11, 669-674.	3.1	808
527	Is a Calculated Total Hip BMD of Clinical Use?. <i>Osteoporosis International</i> , 2000, 11, 368-371.	3.1	7
528	Risk of Hip Fracture Derived from Relative Risks: An Analysis Applied to the Population of Sweden. <i>Osteoporosis International</i> , 2000, 11, 120-127.	3.1	113
529	Development of a questionnaire (OPQ) to assess patient's knowledge about osteoporosis. <i>Maturitas</i> , 2000, 37, 75-81.	2.4	39
530	Prediction of fracture from low bone mineral density measurements overestimates risk. <i>Bone</i> , 2000, 26, 387-391.	2.9	53
531	Ultrasound velocity and dual-energy X-ray absorptiometry in normal and pagetic bone. <i>Bone</i> , 2000, 26, 525-528.	2.9	15
532	Trabecular architecture in women and men of similar bone mass with and without vertebral fracture: II. three-dimensional histology. <i>Bone</i> , 2000, 27, 277-282.	2.9	107
533	Trabecular architecture in women and men of similar bone mass with and without vertebral fracture: I. two-dimensional histology. <i>Bone</i> , 2000, 27, 271-276.	2.9	104
534	Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. <i>Bone</i> , 2000, 27, 585-590.	2.9	354
535	Comparison of the European and USA Practice Guidelines for Osteoporosis. <i>Trends in Endocrinology and Metabolism</i> , 2000, 11, 28-32.	7.1	42
536	Effect of calcitonin on vertebral and other fractures. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1999, 92, 143-150.	0.5	50
537	Osteoporosis: Who, When, How Long to Treat, and with What Effectiveness?. <i>Drug Information Journal</i> , 1999, 33, 315-319.	0.5	0
538	Economic impact of using clodronate in the management of patients with multiple myeloma. <i>British Journal of Haematology</i> , 1999, 104, 358-364.	2.5	40
539	A high incidence of vertebral fracture in women with breast cancer. <i>British Journal of Cancer</i> , 1999, 79, 1179-1181.	6.4	243
540	Clinical Assessment of Bone Mass, Quality and Architecture. <i>Osteoporosis International</i> , 1999, 9, S24-S28.	3.1	13

#	ARTICLE	IF	CITATIONS
541	Number and Type of Vertebral Deformities: Epidemiological Characteristics and Relation to Back Pain and Height Loss. <i>Osteoporosis International</i> , 1999, 9, 206-213.	3.1	257
542	Quality of Life in Patients with Vertebral Fractures: Validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). <i>Osteoporosis International</i> , 1999, 10, 150-160.	3.1	346
543	Editorial. <i>Bone</i> , 1999, 24, 279-290.	2.9	65
544	The burden of osteoporosis. <i>Journal of Endocrinological Investigation</i> , 1999, 22, 583-588.	3.3	67
545	The distribution, determinants, and clinical correlates of vertebral osteophytosis: a population based survey. <i>Journal of Rheumatology</i> , 1999, 26, 842-8.	2.0	119
546	Circumstances around the fall in a multinational hip fracture risk study: a diverse pattern for prevention. <i>Accident Analysis and Prevention</i> , 1998, 30, 607-616.	5.7	36
547	Short-term Reproducibility of Proximal Femur Bone Mineral Density in the Elderly. <i>Calcified Tissue International</i> , 1998, 63, 296-299.	3.1	25
548	Lifetime Risk of Hip Fractures is Underestimated. <i>Osteoporosis International</i> , 1998, 8, 599-603.	3.1	153
549	A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. <i>British Journal of Haematology</i> , 1998, 100, 317-325.	2.5	292
550	Risk factors in osteoporosis. <i>Maturitas</i> , 1998, 30, 229-233.	2.4	54
551	Advances in osteoporosis. <i>Lancet, The</i> , 1998, 351, 379.	13.7	5
552	Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.. <i>Journal of Clinical Oncology</i> , 1998, 16, 3890-3899.	1.6	350
553	Biochemical markers in osteoporosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1997, 57, 6-11.	1.2	8
554	Alendronate in the treatment of Paget's disease of bone. <i>Bone</i> , 1997, 20, 263-271.	2.9	44
555	Osteoporosis: a view into the next century. <i>Netherlands Journal of Medicine</i> , 1997, 50, 198-203.	0.5	9
556	Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 1700-1707.	2.8	247
557	Bone Density Variation and Its Effects on Risk of Vertebral Deformity in Men and Women Studied in Thirteen European Centers: The EVOS Study. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 1883-1894.	2.8	177
558	Preliminary study on relationship between vertebral fracture and aortic calcification in postmenopausal women. <i>Journal of Bone and Mineral Metabolism</i> , 1997, 15, 218-222.	2.7	3

#	ARTICLE	IF	CITATIONS
559	World-wide Projections for Hip Fracture. <i>Osteoporosis International</i> , 1997, 7, 407-413.	3.1	1,720
560	Vitamin D analogs: From renal bone disease to osteoporosis. <i>Calcified Tissue International</i> , 1997, 60, 106-110.	3.1	4
561	Quality of life as outcome in the treatment of osteoporosis: The development of a questionnaire for quality of life by the European foundation for osteoporosis. <i>Osteoporosis International</i> , 1997, 7, 36-38.	3.1	167
562	The hospital burden of vertebral fracture in Europe: A study of national register sources. <i>Osteoporosis International</i> , 1997, 7, 138-141.	3.1	84
563	Guidelines for diagnosis and management of osteoporosis. <i>Osteoporosis International</i> , 1997, 7, 390-406.	3.1	713
564	Bone density measurements and osteoporosis. <i>Journal of Internal Medicine</i> , 1997, 241, 173-175.	6.0	6
565	Bone turnover and biochemical markers in malignancy. <i>Cancer</i> , 1997, 80, 1538-1545.	4.1	63
566	Clodronate. <i>Cancer</i> , 1997, 80, 1691-1695.	4.1	15
567	Bone turnover and biochemical markers in malignancy. <i>Cancer</i> , 1997, 80, 1538-1545.	4.1	16
568	Biochemical markers in osteoporosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1997, 57, 6-11.	1.2	5
569	Biochemical markers in osteoporosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation, Supplement</i> , 1997, 227, 6-11.	2.7	1
570	Clodronate. <i>Cancer</i> , 1997, 80, 1691-1695.	4.1	5
571	Clodronate decreases the frequency of skeletal metastases in women with breast cancer. <i>Bone</i> , 1996, 19, 663-667.	2.9	218
572	Duration of response with oral clodronate in Paget's disease of bone. <i>Bone</i> , 1996, 18, 185-190.	2.9	160
573	Paget's disease of bone and unvaccinated dogs. <i>Bone</i> , 1996, 19, 47-50.	2.9	46
574	Evaluation of the risk of hip fracture. <i>Bone</i> , 1996, 18, S127-S132.	2.9	57
575	8 The menopause and the skeleton: key issues. <i>Bailliere's Clinical Obstetrics and Gynaecology</i> , 1996, 10, 469-481.	0.6	3
576	The GREES Recommendations for the Registration of New Drugs in the Prevention and Treatment of Osteoporosis. <i>Calcified Tissue International</i> , 1996, 59, 410-411.	3.1	0

#	ARTICLE	IF	CITATIONS
577	Effect of pulsed electromagnetic fields on bone formation and bone loss during limb lengthening. <i>Bone</i> , 1996, 18, 505-509.	2.9	99
578	Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.. <i>Journal of Clinical Oncology</i> , 1996, 14, 78-84.	1.6	624
579	Rationale for the Use of Bisphosphonates in Breast Cancer. <i>Acta OncolÃ³gica</i> , 1996, 35, 61-67.	1.8	14
580	Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: A position paper of the european foundation for osteoporosis and bone disease. <i>Osteoporosis International</i> , 1996, 6, 256-261.	3.1	79
581	Medroxyprogesterone and bone mineral density response to oestrogen. <i>Clinical Endocrinology</i> , 1996, 44, 297-298.	2.4	0
582	Influence of Life Style in the MEDOS Study. <i>Scandinavian Journal of Rheumatology</i> , 1996, 25, 112-112.	1.1	12
583	A Mental-functional Risk Score for Prediction of Hip Fracture. <i>Age and Ageing</i> , 1996, 25, 439-442.	1.6	19
584	Comparison of three intravenous regimens of clodronate in paget disease of bone. <i>Journal of Bone and Mineral Research</i> , 1996, 11, 178-182.	2.8	26
585	The prevalence of vertebral deformity in European men and women: The european vertebral osteoporosis study. <i>Journal of Bone and Mineral Research</i> , 1996, 11, 1010-1018.	2.8	783
586	Estrogens, the menopause, and osteoporosis. <i>Bone</i> , 1996, 19, S185-S190.	2.9	56
587	A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. <i>British Journal of Cancer</i> , 1995, 72, 1289-1293.	6.4	152
588	The use of alfacalcidol in the prevention of bone disease in early renal failure. <i>Nephrology Dialysis Transplantation</i> , 1995, 10, 23-28.	0.7	2
589	Rationale for the use of alendronate in osteoporosis. <i>Osteoporosis International</i> , 1995, 5, 1-13.	3.1	73
590	Influence of age and body mass on the effects of vitamin d on hip fracture risk. <i>Osteoporosis International</i> , 1995, 5, 450-454.	3.1	25
591	Acute effects of deflazacort and prednisone on rates of mineralization and bone formation. <i>Calcified Tissue International</i> , 1995, 56, 109-112.	3.1	18
592	Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.. <i>Journal of Clinical Oncology</i> , 1995, 13, 929-934.	1.6	59
593	Sustained response to intravenous alendronate in postmenopausal osteoporosis. <i>Bone</i> , 1995, 17, 517-520.	2.9	32
594	How to assess drug efficacy in osteoporosis. <i>Lancet, The</i> , 1995, 345, 743-744.	13.7	12

#	ARTICLE	IF	CITATIONS
595	Perspectives assessment of involuntional bone loss: Methodological and conceptual problems. Journal of Bone and Mineral Research, 1995, 10, 511-517.	2.8	45
596	The effects of intravenous alendronate in Paget's disease of bone. Journal of Bone and Mineral Research, 1995, 10, 1094-1100.	2.8	27
597	Risk factors for hip fracture in european women: The MEDOS study. Journal of Bone and Mineral Research, 1995, 10, 1802-1815.	2.8	472
598	Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ: British Medical Journal, 1995, 310, 358-363.	2.3	279
599	Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. QJM - Monthly Journal of the Association of Physicians, 1995, 88, 135-9.	0.5	27
600	Treatment of osteoporosis in elderly women. American Journal of Medicine, 1995, 98, 60S-66S.	1.5	10
601	Bone loss after tibial fracture. Evaluated by dual-energy X-ray absorptiometry. Journal of Bone and Joint Surgery: British Volume, 1995, 77, 473-8.	3.4	9
602	Serum type I procollagen peptide: a non-invasive index of bone formation in patients on haemodialysis?. Nephrology Dialysis Transplantation, 1994, 9, 511-516.	0.7	30
603	Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Annals of the Rheumatic Diseases, 1994, 53, 157-157.	0.9	0
604	ALGODYSTROPHY: AN UNDER-RECOGNIZED COMPLICATION OF MINOR TRAUMA. Rheumatology, 1994, 33, 240-248.	1.9	157
605	Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. Osteoporosis International, 1994, 4, 368-381.	3.1	1,856
606	Letters. Osteoporosis International, 1994, 4, 117-119.	3.1	10
607	The variable incidence of hip fracture in Southern Europe: The MEDOS study. Osteoporosis International, 1994, 4, 253-263.	3.1	266
608	Bone loss in the elderly. Osteoporosis International, 1994, 4, S59-S65.	3.1	46
609	Treatment of Paget's disease—An overview. Seminars in Arthritis and Rheumatism, 1994, 23, 254-255.	3.4	4
610	Assessment of optimum duration of therapy with oral dichloromethylene diphosphonate (clodronate) in the treatment of Paget's disease. Seminars in Arthritis and Rheumatism, 1994, 23, 271.	3.4	4
611	The effect of alendronate on renal tubular reabsorption of phosphate. Bone and Mineral, 1994, 27, 51-56.	1.9	7
612	An association between osteoporosis and premenstrual symptoms and postmenopausal symptoms. Bone and Mineral, 1994, 24, 127-134.	1.9	54

#	ARTICLE	IF	CITATIONS
613	Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. <i>Bone</i> , 1994, 15, 161-166.	2.9	170
614	Renal and Nonrenal Clearance of Clodronate in Patients with Malignancy and Renal Impairment. <i>Drug Investigation</i> , 1994, 7, 26-33.	0.6	16
615	Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate). <i>British Journal of Cancer</i> , 1994, 69, 914-917.	6.4	30
616	The diagnosis of osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1994, 9, 1137-1141.	2.8	3,021
617	Calcium nutrition and its implications for osteoporosis. Part I. Children and healthy adults. <i>European Journal of Clinical Nutrition</i> , 1994, 48, 757-67.	2.9	18
618	Calcium nutrition and its implications for osteoporosis. Part II. After menopause. <i>European Journal of Clinical Nutrition</i> , 1994, 48, 833-41.	2.9	15
619	Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. <i>British Journal of Cancer</i> , 1993, 67, 560-563.	6.4	77
620	The assessment of vertebral deformity: A method for use in population studies and clinical trials. <i>Osteoporosis International</i> , 1993, 3, 138-147.	3.1	503
621	Therapeutic strategies in the prevention of hip fracture with drugs affecting bone metabolism. <i>Bone</i> , 1993, 14, 85-87.	2.9	22
622	What Constitutes Evidence for Drug Efficacy in Osteoporosis?. <i>Drugs and Aging</i> , 1993, 3, 391-399.	2.7	20
623	Differentiation of heterogeneous phenotypes in human osteoblastt cultures in response to 1,25-dihydroxyvitamin D3. <i>Bone</i> , 1993, 14, 763-767.	2.9	12
624	Methods of assessing new bone formation during limb lengthening. Ultrasonography, dual energy X-ray absorptiometry and radiography compared. <i>Journal of Bone and Joint Surgery: British Volume</i> , 1993, 75-B, 358-364.	3.4	99
625	New bone formation during leg lengthening. Evaluated by dual energy X-ray absorptiometry. <i>Journal of Bone and Joint Surgery: British Volume</i> , 1993, 75-B, 96-106.	3.4	82
626	Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.. <i>Journal of Clinical Oncology</i> , 1993, 11, 59-65.	1.6	563
627	Prevalence of vertebral fracture in women and the relationship with bone density and symptoms: The chingford study. <i>Journal of Bone and Mineral Research</i> , 1993, 8, 817-822.	2.8	121
628	Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.. <i>BMJ: British Medical Journal</i> , 1992, 305, 1124-1128.	2.3	264
629	Epidemiology of osteoporosis. <i>Bone</i> , 1992, 13, S7-S15.	2.9	243
630	Spontaneous Fractures in a Patient Treated with Low Doses of Etidronic Acid (Disodium Etidronate). <i>Drug Safety</i> , 1992, 7, 162-165.	3.2	27

#	ARTICLE	IF	CITATIONS
631	Bone hypertrophy and trabecular generation in Paget's disease and in fluoride-treated osteoporosis. <i>Bone and Mineral</i> , 1992, 17, 399-413.	1.9	19
632	Intravenous alendronate therapy in post-menopausal osteoporosis. <i>Bone and Mineral</i> , 1992, 17, S25.	1.9	2
633	Natural history of skeletal disease in multiple myelomatosis and treatment with clodronate. <i>Bone and Mineral</i> , 1992, 17, S27.	1.9	5
634	Osteoporotic fractures: An unusual presentation of haemochromatosis. <i>Bone</i> , 1992, 13, 431-433.	2.9	41
635	Epidemiology of vertebral osteoporosis. <i>Bone</i> , 1992, 13, S1-S10.	2.9	126
636	The apparent incidence of hip fracture in Europe: A study of national register sources. <i>Osteoporosis International</i> , 1992, 2, 298-302.	3.1	350
637	Quality of life and vertebral osteoporosis. <i>Osteoporosis International</i> , 1992, 2, 161-163.	3.1	49
638	An automated method for the analysis of trabecular bone structure. <i>Journal of Biomedical Informatics</i> , 1992, 25, 1-16.	0.7	35
639	Paleohistology of Paget's disease in two medieval skeletons. <i>American Journal of Physical Anthropology</i> , 1992, 89, 325-331.	2.1	32
640	Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. <i>European Journal of Haematology</i> , 1992, 49, 192-198.	2.2	172
641	Effects of five daily 1 h infusions of alendronate in paget's disease of bone. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 81-87.	2.8	32
642	Bone-density measurement. <i>Lancet, The</i> , 1992, 339, 370-1.	13.7	11
643	The effect of sodium fluoride on trabecular architecture. <i>Bone</i> , 1991, 12, 307-310.	2.9	39
644	Familial expansile osteolysis: A morphological, histomorphometric and serological study. <i>Bone</i> , 1991, 12, 331-338.	2.9	47
645	Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy. <i>Bone</i> , 1991, 12, 17-20.	2.9	29
646	1,25(OH)2D3 induces differentiation of osteoclast-like cells from human bone marrow cultures. <i>Biochemical and Biophysical Research Communications</i> , 1991, 176, 1189-1195.	2.1	27
647	Immunoreactivity and proliferative actions of \hat{I}^2 microglobulin on human bone-derived cells in vitro. <i>Biochemical and Biophysical Research Communications</i> , 1991, 175, 795-803.	2.1	27
648	A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. <i>Arthritis and Rheumatism</i> , 1991, 34, 287-295.	6.7	73

#	ARTICLE	IF	CITATIONS
649	Guidelines for clinical trials in Osteoporosis. <i>Osteoporosis International</i> , 1991, 1, 182-188.	3.1	52
650	Actions of calcipotriol (MC 903), a novel vitamin D3 analog, on human bone-derived cells: Comparison with 1,25-dihydroxyvitamin D3. <i>Journal of Bone and Mineral Research</i> , 1991, 6, 1307-1315.	2.8	20
651	Osteoporosis and osteopenia. <i>Journal of Bone and Mineral Research</i> , 1990, 5, 209-211.	2.8	55
652	Treatment of paget's disease of bone with aminohydroxybutylidene bisphosphonate. <i>Journal of Bone and Mineral Research</i> , 1990, 5, 483-491.	2.8	69
653	Bone loss and age-related fractures. <i>Experimental Gerontology</i> , 1990, 25, 289-296.	2.8	11
654	Features of algodystrophy after Colles' fracture. <i>Journal of Bone and Joint Surgery: British Volume</i> , 1990, 72-B, 105-110.	3.4	217
655	Increased potency of 1,25-dihydroxyvitamin D3 on human osteoblast-like cells following structural side-chain modification. <i>Bone</i> , 1990, 11, 439-443.	2.9	5
656	Circulating osteocalcin in primary biliary cirrhosis following liver transplantation and during treatment with ciclosporin. <i>Journal of Hepatology</i> , 1990, 11, 354-358.	3.7	39
657	1,25(OH)2D3 and calcipotriol (MC903) have similar effects on the induction of osteoclast-like cell formation in human bone marrow cultures. <i>Biochemical and Biophysical Research Communications</i> , 1990, 171, 1056-1063.	2.1	18
658	Involvement of prostaglandin E2 in the inhibition of osteocalcin synthesis by human osteoblast-like cells in response to cytokines and systemic hormones. <i>Biochemical and Biophysical Research Communications</i> , 1990, 167, 194-202.	2.1	44
659	Improvement in the deformity of the face in Paget's disease treated with diphosphonates. <i>Journal of Bone and Joint Surgery: British Volume</i> , 1990, 72-B, 132-136.	3.4	22
660	Vitamin D metabolism in myeloma. <i>British Journal of Haematology</i> , 1989, 73, 57-60.	2.5	12
661	Indices of calcium metabolism in women with hip fractures. <i>Bone and Mineral</i> , 1989, 5, 193-200.	1.9	44
662	Fatal Cardiac Zygomycosis in a Renal Transplant Patient Treated with Desferrioxamine. <i>Nephrology Dialysis Transplantation</i> , 1989, 4, 911-913.	0.7	19
663	Calcium supplementation of the diet-II.. <i>BMJ: British Medical Journal</i> , 1989, 298, 205-208.	2.3	88
664	Calcium supplementation of the diet-I.. <i>BMJ: British Medical Journal</i> , 1989, 298, 137-140.	2.3	126
665	Intravenous calcitriol lowers serum calcium concentrations in uraemic patients with severe hyperparathyroidism and hypercalcaemia. <i>Nephrology Dialysis Transplantation</i> , 1989, 4, 545-8.	0.7	11
666	Calcium metabolism and myeloma and the treatment of hypercalcemia. <i>Hematological Oncology</i> , 1988, 6, 115-117.	1.7	1

#	ARTICLE	IF	CITATIONS
667	8 Renal osteodystrophy. Bailliere's Clinical Endocrinology and Metabolism, 1988, 2, 193-241.	1.0	11
668	Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone, 1988, 9, 123-130.	2.9	115
669	Familial expansile osteolysis. A new dysplasia. Journal of Bone and Joint Surgery: British Volume, 1988, 70-B, 255-260.	3.4	89
670	Alkaline phosphatase isoenzymes in serum determined by high-performance anion-exchange liquid chromatography with detection by enzyme reaction. Clinical Chemistry, 1988, 34, 2406-9.	3.2	9
671	Rapid suppression of plasma alkaline phosphatase activity after renal transplantation in patients with osteodystrophy. Clinica Chimica Acta, 1987, 164, 285-291.	1.1	15
672	Paramyxovirus-like inclusions in two cases of pycnodysostosis. Bone, 1987, 8, 211-217.	2.9	42
673	Osteopenia in systemic mastocytosis: Natural history and responses to treatment with inhibitors of bone resorption. Bone, 1987, 8, 149-155.	2.9	56
674	REMISSION OF HYPOPARATHYROIDISM DURING LACTATION: EVIDENCE FOR A PHYSIOLOGICAL ROLE FOR PROLACTIN IN THE REGULATION OF VITAMIN D METABOLISM. Clinical Endocrinology, 1987, 26, 667-674.	2.4	42
675	Aminohexane diphosphonate in the treatment of paget's disease of bone. Journal of Bone and Mineral Research, 1987, 2, 273-279.	2.8	42
676	Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. European Journal of Surgical Oncology, 1987, 13, 41-9.	1.0	85
677	Thallium-pertechnetate subtraction scintigraphy: A quantitative comparison between adenomatous and hyperplastic parathyroid glands. European Journal of Nuclear Medicine and Molecular Imaging, 1986, 12, 31-36.	2.1	18
678	Vitamin D metabolites in patients with established non-union of fracture. Bone and Mineral, 1986, 1, 205-9.	1.9	9
679	Pathogenesis of osteomalacia in chronic renal failure and its relationship to vitamin D. Annales De Médecine Interne, 1986, 137, 193-9.	0.2	1
680	Treatment of malignant hypercalcaemia with clodronate. British Journal of Cancer, 1985, 51, 665-669.	6.4	50
681	Deflazacort a safer systemic steroid for the treatment of chronic dermatoses. British Journal of Dermatology, 1985, 113, 34-35.	1.5	4
682	ABNORMAL VITAMIN D METABOLISM IN PAGET'S DISEASE OF BONE. Clinical Endocrinology, 1985, 22, 559-566.	2.4	11
683	LONG-TERM EFFECTS OF HISTAMINE H ₂ -RECEPTOR ANTAGONISTS ON SERUM PARATHYROID HORMONE IN CHRONIC RENAL FAILURE. Clinical Endocrinology, 1985, 23, 277-282.	2.4	5
684	Assessment of thallium-pertechnetate subtraction scintigraphy in hyperparathyroidism. British Journal of Radiology, 1985, 58, 131-135.	2.2	17

#	ARTICLE	IF	CITATIONS
685	The mechanism of hypocalcaemia following thyroidectomy. European Journal of Endocrinology, 1985, 109, 220-226.	3.7	41
686	Carcinoma of the prostate: remission of paraparesis with inhibitors of bone resorption.. Postgraduate Medical Journal, 1985, 61, 551-553.	1.8	18
687	Comparative effects of an antiviral drug, inosiplex, and diphosphonates in Paget's disease of bone. Bone, 1985, 6, 69-72.	2.9	3
688	Monitoring the treatment of paget's disease with etidronate. Calcified Tissue International, 1984, 36, 629-631.	3.1	18
689	Calcium Metabolism in Osteogenesis Imperfecta. Clinical Science, 1984, 67, 21P-22P.	0.0	0
690	Intravenous Clodronate in the Treatment and Retreatment of Paget's Disease. Clinical Science, 1984, 67, 40P-41P.	0.0	0
691	Aminohexane Diphosphonate (AHDP) for the Treatment of Paget's Disease. Clinical Science, 1984, 67, 73P-74P.	0.0	1
692	The Use of Ethane-1-Hydroxy-1,1-Diphosphonate (EHDP) in the Management of Hormone-Resistant Prostatic Carcinoma. Clinical Science, 1984, 67, 74P-74P.	0.0	0
693	Deflazacort and skeletal, phosphate and glucose metabolism in monkeys. Advances in Experimental Medicine and Biology, 1984, 171, 101-10.	1.6	1
694	Plasma hydroxyproline in uremia: Relationships with histologic and biochemical indices of bone turnover. Metabolic Bone Disease & Related Research, 1983, 4, 297-303.	0.5	13
695	The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma. British Journal of Haematology, 1983, 54, 121-132.	2.5	86
696	THE USE OF DIPHOSPHONATES IN MYELOMA. British Journal of Haematology, 1983, 53, 688-690.	2.5	1
697	SERUM ALUMINIUM MEASUREMENTS IN RENAL BONE DISEASE. Lancet, The, 1983, 321, 1168-1169.	13.7	14
698	Calcium Metabolism in Subjects Living with a Permanent Ileostomy. Digestion, 1983, 26, 131-136.	2.3	3
699	Drug Treatment of Primary Hyperparathyroidism: Use of Clodronate Disodium. Journal of Urology, 1983, 130, 840-840.	0.4	0
700	Vitamin A and hyperparathyroid bone disease in uremia. American Journal of Clinical Nutrition, 1983, 38, 914-920.	4.7	11
701	Long-term treatment of osteoporosis with 24,25 dihydroxycholecalciferol. European Journal of Endocrinology, 1982, 101, 636-640.	3.7	14
702	1,25(OH) ₂ D ₃ Binding Protein from Normal Pig Intestine: Characterisation and its Use in the Assay of Serum 1,25(OH) ₂ D ₃ Concentrations. Clinical Science, 1982, 62, 56P-57P.	4.3	0

#	ARTICLE	IF	CITATIONS
703	DETERIORATION OF RENAL BONE DISEASE IN PATIENTS TREATED WITH SALMON CALCITONIN. <i>Clinical Endocrinology</i> , 1982, 16, 29-37.	2.4	14
704	Vitamin D metabolism and its clinical application. <i>Journal of Bone and Joint Surgery: British Volume</i> , 1982, 64-B, 542-560.	3.4	44
705	Effect of vitamin D2 on the assay of 24,25-dihydroxyvitamin D3 in man. <i>Mineral and Electrolyte Metabolism</i> , 1982, 7, 15-9.	1.1	0
706	The Diagnostic and Aetiological Significance of Certain Ultrastructural Features of the Osteoclasts in Paget's Disease of Bone. <i>Clinical Science</i> , 1981, 60, 11P-11P.	4.3	1
707	Responses to salmon calcitonin in chronic renal failure: relation to histological and biochemical indices of bone turnover. <i>European Journal of Clinical Investigation</i> , 1981, 11, 177-184.	3.4	10
708	Lack of clinical and physiological relationship between gastrin and calcitonin in man. <i>European Journal of Clinical Investigation</i> , 1981, 11, 331-335.	3.4	12
709	Effects of 24,25-dihydroxy-vitamin D3 on its plasma level in man. <i>Metabolic Bone Disease & Related Research</i> , 1981, 3, 155-158.	0.5	8
710	Diphosphonates and paget's disease of bone. <i>Metabolic Bone Disease & Related Research</i> , 1981, 3, 217.	0.5	2
711	Paget's bloom of bone : Diagnosis and management. <i>Metabolic Bone Disease & Related Research</i> , 1981, 3, 219-230.	0.5	13
712	Biochemical markers of bone turnover in paget's disease. <i>Metabolic Bone Disease & Related Research</i> , 1981, 3, 255-262.	0.5	35
713	Paget's disease: Improvement of spinal cord dysfunction with diphosphonates and Calcitonin. <i>Metabolic Bone Disease & Related Research</i> , 1981, 3, 327-335.	0.5	20
714	The role of vitamin D metabolites in the osteomalacia of renal disease. <i>Current Medical Research and Opinion</i> , 1981, 7, 294-315.	1.9	10
715	Comparison of acute effects of 1.25- and 24.25-dihydroxy-vitamin D3 in normal subjects. <i>European Journal of Endocrinology</i> , 1981, 98, 619-624.	3.7	6
716	The pathophysiology of hypercaemia. <i>Metabolic Bone Disease & Related Research</i> , 1980, 2, 151-159.	0.5	23
717	Physiology and pharmacological regulation of bone resorption. <i>Metabolic Bone Disease & Related Research</i> , 1980, 2, 177-189.	0.5	20
718	An Evaluation of 1 α -Hydroxy-and 1,25-Dihydroxyvitamin D3 in the Treatment of Renal Bone Disease. <i>Contributions To Nephrology</i> , 1980, 18, 12-28.	1.1	9
719	ETHANOLINDUCED SECRETION OF CALCITONIN IN CHRONIC RENAL DISEASE. <i>Clinical Endocrinology</i> , 1979, 10, 155-161.	2.4	11
720	The biological effects of 1, 24, 25-Trihydroxyvitamin D3 in man. <i>Metabolic Bone Disease & Related Research</i> , 1979, 1, 295-298.	0.5	7

#	ARTICLE	IF	CITATIONS
721	The Absence of 24,25-Dihydroxycholecalciferol in Anephric Patients. <i>Clinical Science and Molecular Medicine Supplement</i> , 1978, 55, 541-547.	0.5	22
722	Evidence for a Direct Effect of 24,25-Dihydroxycholecalciferol on Intestinal Absorption of Calcium. <i>Clinical Science and Molecular Medicine</i> , 1978, 54, 23P-24P.	0.8	0
723	Renal disease and disorders of calcium metabolism. <i>Comprehensive Therapy</i> , 1978, 4, 44-50.	0.2	0
724	Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.. <i>Archives of Disease in Childhood</i> , 1977, 52, 473-481.	1.9	34
725	Changes in Histologic and Biochemical Indexes of Bone Turnover after Bilateral Nephrectomy in Patients on Hemodialysis. <i>New England Journal of Medicine</i> , 1977, 296, 1073-1079.	27.0	53
726	Plasma Calcitonin in Paget's Disease of Bone. <i>Clinical Science and Molecular Medicine</i> , 1977, 52, 329-332.	0.8	12
727	Osteomalacia associated with increased renal tubular resorption of phosphate (hypohyperparathyroidism). <i>Postgraduate Medical Journal</i> , 1976, 52, 295-297.	1.8	8
728	Mixed sclerosing bone dystrophy with regression of melorheostosis. <i>British Journal of Radiology</i> , 1975, 48, 400-402.	2.2	20
729	An estimate of the turnover rate of bone-derived plasma alkaline phosphatase in paget's disease. <i>Clinica Chimica Acta</i> , 1975, 63, 227-229.	1.1	41
730	The use of anticoagulants in bacterial endocarditis. <i>Postgraduate Medical Journal</i> , 1974, 50, 312-313.	1.8	26
731	SERIAL ASSAYS OF PLASMA GROWTH HORMONE IN TREATED AND UNTREATED ACROMEGALY. <i>Journal of Endocrinology</i> , 1974, 63, 21-34.	2.6	18
732	Population screening for fracture risk in postmenopausal women – a logical step in reducing the osteoporotic fracture burden?. <i>Osteoporosis International</i> , 0, , .	3.1	2